WO2023190529A1 - Method for producing milk protein degradation product - Google Patents

Method for producing milk protein degradation product Download PDF

Info

Publication number
WO2023190529A1
WO2023190529A1 PCT/JP2023/012550 JP2023012550W WO2023190529A1 WO 2023190529 A1 WO2023190529 A1 WO 2023190529A1 JP 2023012550 W JP2023012550 W JP 2023012550W WO 2023190529 A1 WO2023190529 A1 WO 2023190529A1
Authority
WO
WIPO (PCT)
Prior art keywords
milk protein
milk
less
derived
molecular weight
Prior art date
Application number
PCT/JP2023/012550
Other languages
French (fr)
Japanese (ja)
Inventor
創 中田
智弘 椎名
Original Assignee
森永乳業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 森永乳業株式会社 filed Critical 森永乳業株式会社
Publication of WO2023190529A1 publication Critical patent/WO2023190529A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00Working-up of proteins for foodstuffs
    • A23J3/04Animal proteins
    • A23J3/08Dairy proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00Working-up of proteins for foodstuffs
    • A23J3/30Working-up of proteins for foodstuffs by hydrolysis
    • A23J3/32Working-up of proteins for foodstuffs by hydrolysis using chemical agents
    • A23J3/34Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof

Definitions

  • the present invention relates to a method for producing a milk protein decomposition product.
  • formula milk For the prevention and treatment of food allergies in infants, anti-allergic formula milk with reduced protein antigenicity is used.
  • Such formula milk generally contains milk proteins such as whey protein and casein that have been hydrolyzed to reduce their antigenicity.
  • milk protein as a nitrogen source in formula milk is usually blended as a decomposed product.
  • the fat in formula milk be emulsified.
  • the emulsifying properties of milk protein decomposition products are lower than that of milk proteins, and when preparing milk with milk protein decomposition products and fat, it is difficult to maintain an emulsified state in which fat globules are completely dispersed. Even if emulsification is performed using a normal homogenizer (for example, a homogenizer that passes through a homogenizer valve), fat globules easily aggregate and exhibit a state of fat separation, resulting in fat separation in the upper layer of the liquid.
  • a normal homogenizer for example, a homogenizer that passes through a homogenizer valve
  • Patent Document 1 discloses that whey protein is degraded using a combination of three enzymes: endoprotease derived from Bacillus subtilis, trypsin derived from pigs, and papain, resulting in emulsifying properties, thermostability, and low antigenicity. It is disclosed that an excellent milk protein decomposition product can be produced. It has also been reported that trypsin or chymotrypsin derived from microorganisms is used when decomposing milk proteins to produce milk protein decomposition products (Patent Documents 2 to 5, etc.).
  • Patent No. 3226695 International Publication No. 2012/042013 International Publication No. 2010/112546 JP2000-063284 Japanese Patent Application Publication No. 6-343422
  • an object of the present invention is to provide a method for obtaining a milk protein decomposition product that is a low molecular weight peptide but has good emulsifying properties.
  • milk proteins can be synthesized using a combination of three types of proteolytic enzymes: trypsin-like endoprotease derived from microorganisms, endoprotease derived from Bacillus bacteria, and papain. It was discovered that the above problems could be solved by disassembling it, and the present invention was completed.
  • a method for producing a milk protein decomposition product comprising: comprising a proteolytic step of causing a proteolytic enzyme to act on the milk protein,
  • the proteolytic enzyme includes a trypsin-like endoprotease derived from a microorganism, an endoprotease derived from a Bacillus bacterium, and papain
  • the production method wherein the milk protein decomposition product has a number average molecular weight of 650 or less.
  • the production method according to [1], wherein the milk protein is whey protein.
  • the present invention provides a method for producing a milk protein decomposition product that is a peptide with a high degree of decomposition and a low molecular weight but has good emulsifying properties.
  • the milk protein decomposition product produced by this method shows excellent emulsion stability when mixed with fat, has good thermal stability, and has low antigenicity, so it is suitable for blending into formula milk etc. be able to.
  • animal-derived enzymes such as pig-derived enzymes, we can create milk protein decomposition products that meet the standards for certification as halal food, providing products that are suitable for a variety of cultures. You can also.
  • the method for producing a milk protein decomposition product of the present invention includes a proteolysis step in which a proteolytic enzyme is allowed to act on milk protein.
  • the milk protein is not particularly limited as long as it is a milk-derived protein, and examples thereof include whey protein, casein, caseinate, casein rennet, and the like, with whey protein being more preferred.
  • Examples of milk include human, cow, horse, sheep, goat, and pig milk.
  • milk protein decomposition products it is better to avoid proteins derived from pig milk.
  • Whey protein is a commercially available product, whey separated from milk or skim milk by a known method (e.g., cheese whey, acid whey, membrane-separated whey, whey powder, desalted whey powder, etc.), or separated and purified whey protein.
  • a known method e.g., cheese whey, acid whey, membrane-separated whey, whey powder, desalted whey powder, etc.
  • WPC concentrates
  • WPI whey protein isolates
  • casein one or more types selected from commercially available products, casein separated from milk, skim milk, etc. by a known method, and casein produced by genetic recombination technology, etc. can be used. Note that casein is classified into ⁇ -casein, ⁇ -casein, and ⁇ -casein, and any casein can be used in the present invention.
  • proteolytic enzymes used in the production method of the present invention include trypsin-like endoprotease derived from microorganisms, endoprotease derived from Bacillus bacteria, and papain.
  • the trypsin-like endoprotease derived from a microorganism is a serine protease, and its origin is not particularly limited as long as it is a microorganism, but those derived from bacteria of the genus Fusarium are preferred, and those derived from Fusarium oxysporum are more preferred. preferable.
  • One or more types of trypsin-like endoproteases derived from microorganisms may be used. Alternatively, commercially available products may be used.
  • trypsin-like endoproteases derived from microorganisms are not particularly limited, but preferred examples include Formea TL 1200 BG (manufactured by Novozymes) derived from Fusarium oxysporum.
  • the amount of trypsin-like endoprotease derived from microorganisms can be appropriately set depending on the desired yield of milk protein decomposition product, etc., but for example, the upper limit is preferably 20 activity units or less per 1 g of milk protein, 19 activity units or less, 18 activity units or less, 17 activity units or less, 16 activity units or less, 15 activity units or less, 14 activity units or less, 13 activity units or less, 12 activity units or less, 11 activity units or less, more preferably 10 activity units It can be used in an amount of up to 9 active units, up to 8 active units, up to 7 active units, up to 6 active units, more preferably up to 5 active units. Further, the lower limit is not particularly limited, but may be 1 or more activity units per 1 g of milk protein.
  • a suitable range may be any consistent combination of the above upper and lower limits, preferably 1 to 20 activity units per gram of milk protein, more preferably 1 to 10 activity units per gram of milk protein. units, more preferably 1 to 5 active units per gram of milk protein.
  • the activity unit of trypsin-like endo-protease is defined by the amount of enzyme specified according to the method described in WO2021/004817A1 and the like. Specifically, the substrate Ac-Arg-p-nitro-anilide (Ac-Arg-pNA) and/or Ac-Lys-p-nitro-anilide (Ac-Arg-pNA) was heated at 37°C and at pH 8. 0, the amount of enzyme that produces 1 micromole of p-nitroaniline per minute.
  • Endo-type proteases derived from bacteria of the genus Bacillus include endo-type proteases derived from Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, etc. Examples include type proteases. Furthermore, proteases are classified into alkaline proteases, neutral proteases, and acidic proteases, with neutral proteases being more preferred. One or more types of endo-type proteases derived from bacteria of the genus Bacillus may be used. Alternatively, commercially available products may be used.
  • endo-proteases derived from bacteria of the genus Bacillus are not particularly limited; Preferred examples include Neutrase (manufactured by Novozymes) and Neutrase (manufactured by Novozymes).
  • the amount of endo-protease derived from Bacillus bacteria can be appropriately set depending on the desired yield of milk protein decomposition product, etc., but for example, the upper limit is preferably 5000 activity units or less per 1 g of milk protein, 4500 activity units or less, more preferably 4000 activity units or less, 3500 activity units or less, still more preferably 3000 activity units or less can be used, and the lower limit is 500 activity units or more, 600 activity units or more, 700 activity units per gram of milk protein. Above, 800 or more active units, 900 or more active units, more preferably 1000 or more active units can be used.
  • a suitable range may be any combination of the above-mentioned upper and lower limits that is consistent with each other, preferably 500 to 5000 activity units per gram of milk protein, more preferably 1000 to 5000 activity units per gram of milk protein. 4000 activity units are used, more preferably 1000 to 3000 activity units per gram of milk protein.
  • the activity unit of endo-type protease derived from bacteria of the genus Bacillus is defined as the amount of enzyme that causes an increase in the colored substance of Folin reagent corresponding to 1 ⁇ g of L-tyrosine per minute at 37°C and pH 7 against the substrate casein. say.
  • Papain is a cysteine protease derived from papaya.
  • One or more types of papain may be used.
  • commercially available products may be used.
  • Commercial products of papain are not particularly limited, but preferred examples include papain W-40 (manufactured by Amano Enzyme), purified papain (manufactured by Asahi Breweries), and the like.
  • the amount of papain used can be appropriately set depending on the desired yield of milk protein decomposition products, etc., but for example, the upper limit is preferably 5000 activity units or less, more preferably 4000 activity units or less per 1 g of milk protein. , 3500 activity units or less, more preferably 3000 activity units or less, and the lower limit is 500 activity units or more, 600 activity units or more, 700 activity units or more, 800 activity units or more, 900 activity units or more, More preferably, it can be used in an amount of 1000 or more active units, and still more preferably 1500 or more active units.
  • a suitable range may be any combination of the above-mentioned upper and lower limits that is consistent with each other, preferably 500 to 5000 activity units per gram of milk protein, more preferably 1000 to 5000 activity units per gram of milk protein. 4000 activity units are used, more preferably 1500 to 3000 activity units per gram of milk protein.
  • the activity unit of papain refers to the amount of enzyme that can increase the amount of absorption at a wavelength of 275 nm corresponding to 1 ⁇ g of tyrosine per minute at 38° C. and pH 6 with respect to the substrate casein.
  • a trypsin-like endoprotease derived from a microorganism an endoprotease derived from a Bacillus bacterium, and papain are used in combination, but other proteolytic enzymes may be used as long as they do not impair the effects of the present invention. It's okay.
  • examples of other proteolytic enzymes include those derived from animals, microorganisms, and plants; however, in the present invention, it is preferable not to use substantially animal-derived proteolytic enzymes.
  • substantially not used does not mean not only that no animal-derived protease is used at all, but also that the milk proteolytic activity of the animal-derived protease cannot be measured or that the milk protein degradation activity of the animal-derived protease is not used. Even if the proteolytic activity can be measured, it is lower than the degrading activity of the three types of proteolytic enzymes mentioned above, and the animal-derived protease is contained to the extent that it is not effective as a protease, and the technology to which the present invention belongs This also means that it is negligible from the perspective of a person skilled in the art.
  • substantially no animal-derived proteases means that when the milk proteolytic activity of trypsin-like endoprotease derived from microorganisms, endoprotease derived from Bacillus bacteria, or papain is taken as 100%, The milk proteolytic activity of the animal-derived protease is 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, 0.5% or less, 0.1% or less, 0.05% or less, or 0. If it is less than 0.01%, it can be said that it is "substantially not used.”
  • oil when referring to "derived from a microorganism,” “derived from a Bacillus bacterium,” or “derived from papain” means that the microorganism or plant originally retains the protease. It doesn't mean anything.
  • a protease produced by introducing a gene encoding a protease produced by a bacterium of the genus Bacillus into Escherichia coli and expressing the same gene is "derived from” a bacterium of the genus Bacillus.
  • Bacillus bacteria that are referred to as "originally possessed by Bacillus bacteria” include not only wild type bacteria, but also those that maintain the ability to produce proteases that have the protease activity and specificity required for the present invention. Recombinants or mutants are included as long as they exist.
  • a proteolytic enzyme is allowed to act on milk proteins.
  • a general procedure will be explained below, but it is not particularly limited thereto.
  • Milk protein as a raw material is dispersed or dissolved in water or hot water.
  • Heat sterilization conditions include, for example, 85°C for 10 minutes, 90°C for 6 minutes, 121°C for 1 minute, and 130°C for 2 seconds.
  • the milk protein liquid after heat sterilization is subjected to ion exchange method using a sodium type or potassium type cation exchange resin (preferably a strongly acidic cation exchange resin), electrodialysis method, ultrafiltration membrane method, or nanofiltration method. Desalination may be performed using a membrane method or the like. For desalting, either a column method or a batch method may be employed.
  • an alkaline agent or an acidic agent to the milk protein solution to adjust the pH to the optimum pH of the hydrolyzing enzyme used or around it.
  • the alkaline agent or acid agent used in the production method of the present invention is not particularly limited as long as it is acceptable for foods or medicines.
  • alkaline agents include sodium hydroxide, potassium hydroxide, potassium carbonate, etc.
  • acid agents include hydrochloric acid, citric acid, phosphoric acid, acetic acid, etc.
  • proteolytic enzyme is added to the milk protein solution, and a reaction is carried out at a temperature of 10 to 85°C for about 0.1 to 48 hours. Note that the enzymatic reactions of the three types of proteolytic enzymes described above may be performed simultaneously or separately.
  • the solution containing the enzyme is maintained at an appropriate temperature depending on the type of enzyme to begin hydrolysis of milk proteins.
  • the temperature may be, for example, 30°C or higher, 40°C or higher, 45°C or higher, or 60°C or lower, or 55°C or lower. Further, any combination of these that does not contradict each other may be used. Note that the suitable temperature range is 30 to 60°C, preferably 45 to 55°C.
  • the hydrolysis reaction time is such that the reaction is continued until a desired decomposition rate is reached while monitoring the decomposition rate of the enzymatic reaction.
  • the decomposition rate In order to obtain decomposition products corresponding to the molecular weights described below, the decomposition rate must be 8% or more, 9% or more, 10% or more, 11% or more, 12% or more, 13% or more, 14% or more, or 15% or more. and 35% or less, 34% or less, 33% or less, 32% or less, 31% or less, 30% or less, 29% or less, 28% or less, 27% or less, 24% or less, 25% or less. Good too. Further, any combination of these that is not contradictory may be used. Note that the preferable range of decomposition rate is 8 to 35%, 10 to 30%, and 15 to 25%.
  • the decomposition rate of milk protein is calculated by measuring the total nitrogen content of the sample using the Kjeldahl method (edited by the Japan Society of Food Industry, “Food Analysis Methods", p. 102, Korin Co., Ltd., 1982), and by measuring the total nitrogen content of the sample.
  • the amount of formol nitrogen in the sample was measured by the titration method (edited by Mitsuda et al., “Food Engineering Experiment Book", Vol. 1, p. 547, Yokendo, 1970), and the decomposition rate was calculated from these measured values using the following formula: do.
  • Decomposition rate (%) formol nitrogen amount ⁇ total nitrogen amount x 100
  • the enzymatic reaction is stopped, for example, by deactivating the enzyme in the hydrolysis solution, and can be carried out by heat deactivation treatment using a conventional method.
  • the heating temperature and holding time of the heat inactivation treatment can be appropriately set to conditions that can sufficiently inactivate the enzyme, taking into consideration the thermal stability of the enzyme used. This can be done with a holding time of ⁇ 30 minutes.
  • the obtained milk protein decomposition product may be subjected to operations such as separation and purification using conventional methods.
  • Purification of milk protein digests is usually carried out using various techniques similar to those used for peptide purification, such as ion-exchange chromatography, adsorption chromatography, reversed-phase chromatography, partition chromatography, and gel filtration chromatography. This can be carried out by appropriately combining methods such as chromatography, solvent precipitation, salting out, distribution between two liquid phases, and the like.
  • the number average molecular weight of the milk protein decomposition product obtained by the production method of the present invention is 650 or less as an upper limit, may be 640 or less, may be 630 or less, may be 620 or less, may be 610 or less, Preferably it may be 600 or less, 590 or less, 580 or less, 570 or less, 560 or less, more preferably 550 or less, 540 or less, 530 or less, and the lower limit is 230 or more, 240 or more, or 250 or more. It may be preferably 260 or more, 270 or more, and more preferably 280 or more. Further, any combination of these that is not contradictory may be used.
  • the average molecular weight of the milk protein decomposition product is determined based on the concept of number average molecular weight below.
  • the number average of Molecular Weight is described, for example, in the literature (edited by The Society of Polymer Science, "Basics of Polymer Science", pp. 116-119, Tokyo Kagaku Dojin Co., Ltd., 1978).
  • the average value of the molecular weight of a polymer compound is shown based on the following different indicators. In other words, high molecular compounds such as milk protein decomposition products are heterogeneous substances and have a distribution of molecular weights, so the molecular weight of milk protein decomposition products must be expressed as an average molecular weight in order to treat them physicochemically.
  • the number average molecular weight (hereinafter sometimes abbreviated as Mn) is the average number of molecules.
  • the average molecular weight of a milk protein decomposition product is measured and calculated by the following method. That is, using high performance liquid chromatography, using a Poly Hydroxyethyl Aspartamide Column (manufactured by Poly LC, diameter 4.6 mm and length 200 mm), the elution rate was adjusted using 20 mM sodium chloride and 50 mM formic acid. Elutes at 0.5 mL/min (Nobuo Ui et al., ed., "High Performance Liquid Chromatography of Proteins and Peptides", Kagaku Special Edition No. 102, p. 241, Kagaku Dojin Co., Ltd., 1984).
  • Detection is performed using a UV detector (manufactured by Shimadzu Corporation), and data is analyzed by a GPC analysis system (manufactured by Shimadzu Corporation) to calculate the number average molecular weight.
  • a protein and/or a peptide with a known molecular weight may be used as appropriate.
  • milk protein decomposition products generally contain free amino acids during the manufacturing process.
  • the milk protein decomposition product obtained by the production method of the present invention is a peptide with a high degree of decomposition and a low molecular weight, but has good emulsifying properties. Due to its good emulsifying properties, it exhibits excellent emulsion stability when mixed with fat. Furthermore, the milk protein decomposition product obtained by the production method of the present invention also has good thermal stability.
  • the milk protein decomposition product obtained by the production method of the present invention has a high degree of decomposition and a low molecular weight, and therefore has reduced antigenicity.
  • casein, ⁇ -lactoglobulin, and the like are examples of antigens that can be a problem with milk proteins and their decomposition products, but the milk protein decomposition products obtained by the production method of the present invention have low antigenicity against these.
  • the antigen residual activity of casein is preferably 2 ppm or less, more preferably 1.5 ppm or less.
  • the antigen residual activity of ⁇ -lactoglobulin is preferably 150 ppm or less, more preferably 100 ppm or less, and still more preferably 75 ppm or less.
  • the milk protein decomposition product obtained by the production method of the present invention can be produced as an excellent milk protein decomposition product without using animal-derived milk protein degrading enzymes, so it is a product that meets the standards to be certified as a halal food. It can be used suitably.
  • the milk protein decomposition product obtained by the production method of the present invention can be used by blending it into medicines, food and drink products, feeds, etc. Since the milk protein decomposition product obtained by the production method of the present invention uses raw materials derived from milk, it is highly safe for living organisms and is suitable for continuous intake over a long period of time. In addition, because it is produced from milk-derived raw materials, which are relatively inexpensive as biomaterials, it can be produced stably and easily in large quantities, and it can also be provided to users at low cost. .
  • the milk protein decomposition product obtained by the production method of the present invention can be preferably included in foods and drinks.
  • foods and drinks also include the form of additives added to foods and drinks and medicines.
  • Such embodiments include, for example, additives added to expressed breast milk or formula milk, and it is assumed that newborns and infants ingest the added milk.
  • Foods and drinks are usually ingested orally, but are not limited to this, and may be ingested nasally, or through a gastrostomy or intestinal fistula.
  • newborns and infants will be fed formula milk, which will be described later, or breast milk to which milk protein decomposition products have been added, through a nasogastric feeding tube or the like.
  • Foods and beverages may be in the form of liquids, pastes, solid gels, powders, etc., such as tablets; bread, macaroni, spaghetti, noodles, cake mixes, flour products such as fried flour and bread crumbs; instant noodles; instant foods such as cup noodles, retort/cooked foods, cooked canned foods, microwave foods, instant soups/stews, instant miso soup/suimono, canned soups, freeze/dried foods, and other instant foods; canned agricultural products, canned fruits, and jams.
  • Processed agricultural products such as marmalade, pickles, boiled beans, dried agricultural products, and cereals (processed grain products); Processed marine products such as canned seafood, fish ham/sausages, fish paste products, seafood delicacies, and boiled fish; Canned livestock products - Processed livestock products such as pastes, meat hams and sausages; Milk and dairy products such as processed milk, milk drinks, yogurts, lactic acid bacteria drinks, cheese, ice creams, creams, and other
  • the "nutritional composition” is not particularly limited as an aspect of food or drink, but preferably includes formula milk, liquid food, supplements, etc., and more preferably formula milk. Ingestion targets may be infants, toddlers, children, or adults, but infants and young children are preferred.
  • Formulated milk includes powdered milk and liquid milk. According to the Ministerial Ordinance Concerning Ingredient Standards for Milk and Dairy Products (Ministerial Ordinance on Milk, etc.), infant formula is defined as ⁇ processed raw milk, cow's milk, special milk, or foods manufactured using these as raw materials, or as a main ingredient, It is defined as a powdered product with added nutrients.
  • Prepared liquid milk is defined in the above ministerial ordinance as "a product made by processing raw milk, cow's milk, special milk, or food products made from these as raw materials, or by adding nutrients necessary for infants and infants to liquid form as a main ingredient.”
  • formula milk contains nutritional ingredients such as various proteins, fats and oils, carbohydrates, minerals, and vitamins, and includes those processed into powder or liquid form.
  • formula milk further includes ⁇ infant formula'', ⁇ infant formula liquid milk'', and ⁇ powdered milk for pregnant women and lactating mothers'', which are foods for special dietary uses stipulated by the Health Promotion Act.
  • Embodiments such as nutritional powder for adults and nutritional powder for the elderly are also included.
  • the feed can also be used as feed as one aspect of food and drink products.
  • the feed include pet food, livestock feed, and fish feed.
  • the form of the feed is not particularly limited and includes, for example, grains such as corn, wheat, barley, rye, and milo; vegetable oil cakes such as soybean oil meal, rapeseed oil meal, coconut oil meal, and linseed oil meal; bran, wheat bran, rice bran, Bran such as defatted rice bran; Manufactured lees such as corn gluten meal and corn jam meal; Animal feed such as fish meal, skim milk powder, whey, yellow grease, and tallow; Yeast such as Torula yeast and brewer's yeast; It may contain mineral feeds such as calcium phosphate and calcium carbonate; oils and fats; simple amino acids; sugars, etc.
  • the milk protein decomposition product obtained by the production method of the present invention may be included in pharmaceuticals as an active ingredient.
  • the pharmaceutical form can be appropriately formulated into a desired dosage form depending on the administration method.
  • solid preparations such as powders, granules, tablets, and capsules; liquid preparations such as solutions, syrups, suspensions, and emulsions.
  • parenteral administration it can be formulated into suppositories, ointments, injections, etc.
  • components such as excipients, pH adjusters, coloring agents, and flavoring agents that are commonly used in formulation can be used.
  • formulation can be carried out by appropriately known methods depending on the dosage form.
  • a pharmaceutical carrier may be added as appropriate.
  • excipients include sugar derivatives such as lactose, sucrose, glucose, mannitol, and sorbitol; starch derivatives such as corn starch, potato starch, ⁇ -starch, dextrin, and carboxymethyl starch; crystalline cellulose, hydroxypropyl cellulose, Cellulose derivatives such as hydroxypropyl methylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium; gum arabic; dextran; pullulan; silicate derivatives such as light silicic anhydride, synthetic aluminum silicate, magnesium aluminate metasilicate; phosphate derivatives such as calcium phosphate; carbonic acid Examples include carbonate derivatives such as calcium; sulfate derivatives such as calcium sulfate.
  • binder examples include, in addition to the excipients mentioned above, gelatin; polyvinylpyrrolidone; macrogol, and the like.
  • disintegrant examples include, in addition to the above excipients, chemically modified starch or cellulose derivatives such as croscarmellose sodium, sodium carboxymethyl starch, and crosslinked polyvinylpyrrolidone.
  • lubricants include talc; stearic acid; stearic acid metal salts such as calcium stearate and magnesium stearate; colloidal silica; waxes such as vegum and gay wax; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid. ; carboxylic acid sodium salts such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids such as silicic anhydride and silicic acid hydrate; starch derivatives, etc. It will be done.
  • the stabilizer examples include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol, and phenylethyl alcohol; benzalkonium chloride; acetic anhydride; and sorbic acid.
  • flavoring agents include sweeteners, acidulants, fragrances, and the like.
  • carriers used in the case of liquid preparations for oral administration include solvents such as water.
  • ratio (%) of each molecular weight range] [area of each molecular weight range in the molecular weight distribution/total area (total area) of milk protein decomposition products in the molecular weight distribution]. was calculated.
  • the number average molecular weight and weight average molecular weight are also shown in Table 1.
  • the degree of decomposition (degradation rate) of milk protein decomposition product was measured by formol titration method. Specifically, the sample powder was dissolved in deionized water at a concentration of 10% w/w, 30 mL of deionized water was added to 4 mL of the solution, and 0.1M hydroxide was added using a pH meter while stirring with a stirrer. The pH was adjusted to 6.80 by dropping sodium solution or 0.1M hydrochloric acid solution. After adding 5 mL of 37% formalin solution adjusted to pH 8.0, the mixture was titrated with 0.1 M sodium hydroxide solution to adjust the pH to 7.90 (x mL).
  • Emulsion stability when milk protein decomposition product was mixed with water and fats and oils was evaluated. Specifically, 10 g of sample powder was dissolved in 150 mL of deionized water, 100 g of soybean oil (manufactured by Fuji Film Wako Pure Chemical Industries, Ltd.) was added, and the mixture was passed through a homogenizer (T.K. ) Emulsified at a pressure of 5000 rpm using Tokushu Kika Kogyo Co., Ltd. (currently Primix Co., Ltd.).
  • the resulting emulsion was placed in a graduated cylinder and stored at room temperature for 24 hours, and then the heights of the oil layer, emulsion layer, and water layer were measured, and the ratio to the entire liquid was calculated.
  • the emulsion after storage was visually observed and evaluated as ⁇ if there was no separation of oil or fat, ⁇ if there was some separation, and ⁇ if there was separation. The results are also shown in Table 1.
  • the antigenicity of the milk protein decomposition product was evaluated. Specifically, using Morinaga FASPEK Elizer II (manufactured by Morinaga Bioscience Institute), the sample powder was diluted 20 times with sample diluent I from the kit, and the total peptide concentration in the diluted solution was 1 to 50 ng/mL. It was prepared so that 100 ⁇ L of the diluted solution was poured into each plastic well on which the primary antibody had been immobilized, and incubated for 1 hour. After washing the plastic well with the prepared washing solution, the enzyme-labeled antibody was reacted for 30 minutes. The detection targets were epitopes contained in the sequences of casein and ⁇ -lactoglobulin, respectively.
  • the milk protein decomposition product prepared by the production method of the present invention is degraded to a low molecular weight with a high decomposition rate, but has high emulsion stability with little separation of fats and oils and water. It is also found that it has excellent thermal stability and antigenicity.
  • a milk protein decomposition product was produced in the same manner as in Test Example 1 using the enzymes and their usage amounts shown in Table 2, and the molecular weight measurement, degradation rate measurement, emulsion stability evaluation, thermal stability evaluation, and antigenicity were determined. We conducted an evaluation. The results are also shown in Table 2. It can be seen that although the milk protein decomposition product prepared by the production method of the present invention is decomposed to a low molecular weight with a high decomposition rate, there is little separation of fats and water from oil and water, and the emulsion stability is high. It is also found that it has excellent thermal stability and antigenicity.
  • the present invention is useful in the fields of pharmaceuticals, food and drink, feed, etc.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention addresses the problem of providing a method for obtaining a milk protein degradation product which has good emulsifiability despite a low-molecular-weight peptide. A method for producing a milk protein degradation product comprises a protein degradation step in which a proteolytic enzyme is made to act on the milk protein, wherein: the proteolytic enzyme comprises a trypsin-like endo-type protease derived from microorganisms, an endo-type protease derived from bacteria belonging to the genus Bacillus, and papain; and the number average molecular weight of the milk protein degradation product is 650 or less.

Description

乳タンパク質分解物の製造方法Method for producing milk protein decomposition product
 本発明は、乳タンパク質分解物の製造方法等に関する。 The present invention relates to a method for producing a milk protein decomposition product.
 乳幼児における食物アレルギーの予防や治療においては、タンパク質の抗原性を低下させた抗アレルギー性調製乳が使用される。かかる調製乳においては、一般にホエイタンパク質やカゼイン等の乳タンパク質を加水分解して抗原性を低下させたものが配合される。また、消化性の観点からも、調製乳における窒素源としての乳タンパク質は、分解物として配合されるのが通常である。 For the prevention and treatment of food allergies in infants, anti-allergic formula milk with reduced protein antigenicity is used. Such formula milk generally contains milk proteins such as whey protein and casein that have been hydrolyzed to reduce their antigenicity. Furthermore, from the viewpoint of digestibility, milk protein as a nitrogen source in formula milk is usually blended as a decomposed product.
 調製乳の脂肪の吸収を良好にするためには、調製乳中の脂肪が乳化されていることが望ましいとされている。しかしながら、一般に乳タンパク質分解物の乳化性は乳タンパク質よりも低く、乳タンパク質分解物と脂肪とで調製乳を製造する場合、脂肪球が完全に分散した乳化状態を維持することは困難であり、通常の均質機(例えば均質バルブを通過させるホモジナイザー)で乳化を行っても、脂肪球が容易に凝集して脂肪分離状態を呈し、液の上層部に脂肪が分離してしまう。 In order to improve the absorption of fat in formula milk, it is considered desirable that the fat in formula milk be emulsified. However, in general, the emulsifying properties of milk protein decomposition products are lower than that of milk proteins, and when preparing milk with milk protein decomposition products and fat, it is difficult to maintain an emulsified state in which fat globules are completely dispersed. Even if emulsification is performed using a normal homogenizer (for example, a homogenizer that passes through a homogenizer valve), fat globules easily aggregate and exhibit a state of fat separation, resulting in fat separation in the upper layer of the liquid.
 そのため、従来乳化性に優れた乳タンパク質分解物を求めて、種々の製法が考案されてきた。例えば、特許文献1には、バシラス・サチリス(Bacillus subtilus)由来エンド型プロテアーゼ、豚由来トリプシン、パパインの三種の酵素を組み合わせてホエイタンパク質分解することにより、乳化性、熱安定性、低抗原性に優れた乳タンパク質分解物が製造できることが開示されている。
 また、乳タンパク質を分解して乳タンパク質分解物を製造する際に、微生物由来のトリプシンやキモトリプシンを用いることも報告されている(特許文献2~5等)。
Therefore, various production methods have been devised in search of milk protein decomposition products with excellent emulsifying properties. For example, Patent Document 1 discloses that whey protein is degraded using a combination of three enzymes: endoprotease derived from Bacillus subtilis, trypsin derived from pigs, and papain, resulting in emulsifying properties, thermostability, and low antigenicity. It is disclosed that an excellent milk protein decomposition product can be produced.
It has also been reported that trypsin or chymotrypsin derived from microorganisms is used when decomposing milk proteins to produce milk protein decomposition products (Patent Documents 2 to 5, etc.).
特許第3226695号Patent No. 3226695 国際公開第2012/042013号International Publication No. 2012/042013 国際公開第2010/112546号International Publication No. 2010/112546 特開2000-063284号JP2000-063284 特開平6-343422号Japanese Patent Application Publication No. 6-343422
 前述の通り、調製乳等に配合する乳タンパク質分解物については、低抗原性や消化性等の観点から分解物であるペプチドの分子量を小さくする要請がある。一方で、一般にタンパク質の分解度が高くなるほど乳化性は劣る傾向にある。従来の乳タンパク質分解方法では、必ずしも乳タンパク質分解物の乳化性と低分子化とを両立させることができなかった。
 かかる状況に鑑みて、本発明は低分子量のペプチドでありながら乳化性が良好な乳タンパク質分解物を取得する方法を提供することを課題とする。
As mentioned above, with respect to milk protein decomposition products to be added to formula milk etc., there is a demand for reducing the molecular weight of the peptides that are the decomposition products from the viewpoint of low antigenicity and digestibility. On the other hand, in general, the higher the degree of protein decomposition, the worse the emulsifying property tends to be. Conventional milk protein decomposition methods have not always been able to achieve both emulsifying properties and low molecular weight decomposition of milk protein decomposition products.
In view of this situation, an object of the present invention is to provide a method for obtaining a milk protein decomposition product that is a low molecular weight peptide but has good emulsifying properties.
 本発明者等は鋭意研究を行った結果、微生物由来のトリプシン様エンド型プロテアーゼ、バシラス(Bacillus)属細菌由来のエンド型プロテアーゼ、及びパパインの三種類のタンパク質分解酵素を組み合わせて用いて乳タンパク質を分解すると、上記課題を解決できることを見出し、本発明を完成させた。 As a result of extensive research, the present inventors have found that milk proteins can be synthesized using a combination of three types of proteolytic enzymes: trypsin-like endoprotease derived from microorganisms, endoprotease derived from Bacillus bacteria, and papain. It was discovered that the above problems could be solved by disassembling it, and the present invention was completed.
 すなわち、本発明は以下のとおりである。
[1]乳タンパク質分解物の製造方法であって、
 前記乳タンパク質にタンパク質分解酵素を作用させるタンパク質分解工程を含み、
 前記タンパク質分解酵素が、微生物由来のトリプシン様エンド型プロテアーゼ、バシラス属細菌由来のエンド型プロテアーゼ、及びパパインを含み、
 前記乳タンパク質分解物の数平均分子量が650以下である、製造方法。
[2]前記乳タンパク質がホエイタンパク質である、[1]に記載の製造方法。
[3]前記微生物がフザリウム属細菌である、[1]又は[2]に記載の製造方法。
[4]前記タンパク質分解酵素が、動物由来のプロテアーゼを実質的に含まない、[1]~[3]のいずれかに記載の製造方法。
That is, the present invention is as follows.
[1] A method for producing a milk protein decomposition product, comprising:
comprising a proteolytic step of causing a proteolytic enzyme to act on the milk protein,
The proteolytic enzyme includes a trypsin-like endoprotease derived from a microorganism, an endoprotease derived from a Bacillus bacterium, and papain,
The production method, wherein the milk protein decomposition product has a number average molecular weight of 650 or less.
[2] The production method according to [1], wherein the milk protein is whey protein.
[3] The production method according to [1] or [2], wherein the microorganism is a Fusarium bacterium.
[4] The production method according to any one of [1] to [3], wherein the protease is substantially free of animal-derived proteases.
 本発明により、分解度が高く低分子量のペプチドでありながら乳化性が良好な乳タンパク質分解物を製造する方法が提供される。かかる方法で製造された乳タンパク質分解物は、脂肪と混合した際に優れた乳化安定性を示し、また熱安定性が良好であり、低抗原性でもあるため、調製乳などに好適に配合することができる。
 さらに、豚由来酵素等の動物由来酵素を用いないことで、ハラル食品に認定される基準に適合する乳タンパク質分解物とすることができるため、多様な文化への対応にも適した製品を提供することもできる。
The present invention provides a method for producing a milk protein decomposition product that is a peptide with a high degree of decomposition and a low molecular weight but has good emulsifying properties. The milk protein decomposition product produced by this method shows excellent emulsion stability when mixed with fat, has good thermal stability, and has low antigenicity, so it is suitable for blending into formula milk etc. be able to.
Furthermore, by not using animal-derived enzymes such as pig-derived enzymes, we can create milk protein decomposition products that meet the standards for certification as halal food, providing products that are suitable for a variety of cultures. You can also.
 以下、本発明の実施の形態について、説明する。ただし、本発明は以下の好ましい実施形態に限定されず、本発明の範囲内で自由に変更することができるものである。なお、本明細書において、数値範囲を「下限~上限」で表現するものに関しては、上限は「以下」であっても「未満」であってもよく、下限は「以上」であっても「超」であってもよい。 Embodiments of the present invention will be described below. However, the present invention is not limited to the following preferred embodiments, and can be freely modified within the scope of the present invention. In addition, in this specification, when a numerical range is expressed as "lower limit to upper limit", the upper limit may be "less than or equal to" or "less than", and the lower limit may be "more than" or "more than". It may be "super".
 本発明の乳タンパク質分解物の製造方法は、乳タンパク質にタンパク質分解酵素を作用させるタンパク質分解工程を含む。
 乳タンパク質としては、乳由来のタンパク質であれば特に限定されず、ホエイタンパク質、カゼイン、カゼイネート、カゼインレンネット等が挙げられ、ホエイタンパク質がより好ましい。乳は、ヒト、ウシ、ウマ、ヒツジ、ヤギ、ブタ等の乳が挙げられる。なお、乳タンパク質分解物を、ハラル食品に適用する場合は、ブタの乳由来のタンパク質は避けた方がよい。
 ホエイタンパク質は、市販品、乳や脱脂乳等から公知の方法により分離されたホエイ(たとえば、チーズホエイ、酸ホエイ、膜分離ホエイ、ホエイ粉末、脱塩ホエイ粉末等)、若しくは分離精製したホエイタンパク質濃縮物(WPC)、ホエイタンパク質単離物(WPI)、又は遺伝子組み換え技術等によって生産されたもの等から選ばれる一種又は二種以上を用いることができる。
 カゼインは、市販品、乳や脱脂乳等から公知の方法により分離されたカゼイン、又は遺伝子組み換え技術等によって生産されたもの等から選ばれる一種又は二種以上を用いることができる。なお、カゼインは、α-カゼイン、β-カゼイン、およびκ-カゼインに分類されるが、本発明にはいずれのカゼインも用いることができる。
The method for producing a milk protein decomposition product of the present invention includes a proteolysis step in which a proteolytic enzyme is allowed to act on milk protein.
The milk protein is not particularly limited as long as it is a milk-derived protein, and examples thereof include whey protein, casein, caseinate, casein rennet, and the like, with whey protein being more preferred. Examples of milk include human, cow, horse, sheep, goat, and pig milk. In addition, when applying milk protein decomposition products to halal foods, it is better to avoid proteins derived from pig milk.
Whey protein is a commercially available product, whey separated from milk or skim milk by a known method (e.g., cheese whey, acid whey, membrane-separated whey, whey powder, desalted whey powder, etc.), or separated and purified whey protein. One or more types selected from concentrates (WPC), whey protein isolates (WPI), those produced by genetic recombination technology, etc. can be used.
As the casein, one or more types selected from commercially available products, casein separated from milk, skim milk, etc. by a known method, and casein produced by genetic recombination technology, etc. can be used. Note that casein is classified into α-casein, β-casein, and κ-casein, and any casein can be used in the present invention.
 本発明の製造方法に用いるタンパク質分解酵素は、微生物由来のトリプシン様エンド型プロテアーゼ、バシラス属細菌由来のエンド型プロテアーゼ、及びパパインを含む。 The proteolytic enzymes used in the production method of the present invention include trypsin-like endoprotease derived from microorganisms, endoprotease derived from Bacillus bacteria, and papain.
 微生物由来のトリプシン様エンド型プロテアーゼは、セリンプロテアーゼであり、由来は微生物であれば特に限定されないが、フザリウム(Fusarium)属細菌由来のものが好ましく、フザリウム・オキシスポルム(Fuzarium oxysporum)由来のものがより好ましい。微生物由来のトリプシン様エンド型プロテアーゼは、一種又は二種以上用いてもよい。また、市販品を用いてもよい。
 微生物由来のトリプシン様エンド型プロテアーゼの市販品としては、特に限定されないがフザリウム・オキシスポルム由来のFormea TL 1200 BG(ノボザイムズ社製)等を好ましく挙げられる。
The trypsin-like endoprotease derived from a microorganism is a serine protease, and its origin is not particularly limited as long as it is a microorganism, but those derived from bacteria of the genus Fusarium are preferred, and those derived from Fusarium oxysporum are more preferred. preferable. One or more types of trypsin-like endoproteases derived from microorganisms may be used. Alternatively, commercially available products may be used.
Commercially available trypsin-like endoproteases derived from microorganisms are not particularly limited, but preferred examples include Formea TL 1200 BG (manufactured by Novozymes) derived from Fusarium oxysporum.
 微生物由来のトリプシン様エンド型プロテアーゼの使用量は、目的とする乳タンパク質分解物の収量等に応じて適宜設定することができるが、例えば、上限値として好ましくは乳タンパク質1g当たり20活性単位以下、19活性単位以下、18活性単位以下、17活性単位以下、16活性単位以下、15活性単位以下、14活性単位以下、13活性単位以下、12活性単位以下、11活性単位以下、より好ましくは10活性単位以下、9活性単位以下、8活性単位以下、7活性単位以下、6活性単位以下、さらに好ましくは5活性単位以下用いることができる。また下限値は特に限定されないが乳タンパク質1g当たり1活性単位以上であってよい。好適な範囲としては、前述の上限値と下限値の矛盾のない任意の組み合わせの範囲であってよく、好ましくは乳タンパク質1g当たり1~20活性単位、より好ましくは乳タンパク質1g当たり1~10活性単位、さらに好ましくは乳タンパク質1g当たり1~5活性単位を用いる。
 ここで、トリプシン様エンド型プロテアーゼの活性単位は、WO2021/004817A1等の記載の方法に従って特定される酵素量により定義される。具体的には、基質Ac-Arg-p-nitro-anilide(Ac-Arg-pNA)および/またはAc-Lys-p-nitro-anilide(Ac-Arg-pNA)に対して、37℃、pH8.0で、1分間に1マイクロモルのp-ニトロアニリンを生成する酵素量をいう。
The amount of trypsin-like endoprotease derived from microorganisms can be appropriately set depending on the desired yield of milk protein decomposition product, etc., but for example, the upper limit is preferably 20 activity units or less per 1 g of milk protein, 19 activity units or less, 18 activity units or less, 17 activity units or less, 16 activity units or less, 15 activity units or less, 14 activity units or less, 13 activity units or less, 12 activity units or less, 11 activity units or less, more preferably 10 activity units It can be used in an amount of up to 9 active units, up to 8 active units, up to 7 active units, up to 6 active units, more preferably up to 5 active units. Further, the lower limit is not particularly limited, but may be 1 or more activity units per 1 g of milk protein. A suitable range may be any consistent combination of the above upper and lower limits, preferably 1 to 20 activity units per gram of milk protein, more preferably 1 to 10 activity units per gram of milk protein. units, more preferably 1 to 5 active units per gram of milk protein.
Here, the activity unit of trypsin-like endo-protease is defined by the amount of enzyme specified according to the method described in WO2021/004817A1 and the like. Specifically, the substrate Ac-Arg-p-nitro-anilide (Ac-Arg-pNA) and/or Ac-Lys-p-nitro-anilide (Ac-Arg-pNA) was heated at 37°C and at pH 8. 0, the amount of enzyme that produces 1 micromole of p-nitroaniline per minute.
 バシラス属細菌由来のエンド型プロテアーゼは、バシラス・サチリス(Bacillus subtilus)、バシラス・リケニフォルミス(Bacillus licheniformis)、バシラス・アミロリクエファシエンス(Bacillus amyloliquefaciens)などに由来するエンド型プロテアーゼが例示される。また、プロテアーゼは、アルカリ性プロテアーゼ、中性プロテアーゼ及び酸性プロテアーゼに分類されるところ、中性プロテアーゼがより好ましい。
 バシラス属細菌由来のエンド型プロテアーゼは、一種又は二種以上用いてもよい。また、市販品を用いてもよい。
Endo-type proteases derived from bacteria of the genus Bacillus include endo-type proteases derived from Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, etc. Examples include type proteases. Furthermore, proteases are classified into alkaline proteases, neutral proteases, and acidic proteases, with neutral proteases being more preferred.
One or more types of endo-type proteases derived from bacteria of the genus Bacillus may be used. Alternatively, commercially available products may be used.
 バシラス属細菌由来のエンド型プロテアーゼの市販品としては、特に限定されないが、例えば、ビオプラーゼSP-20(ナガセケムテックス社製)、プロチンSD-AY50(天野エンザイム社製)、プロテアーゼNアマノ(天野エンザイム社製)、ニュートラーゼ(ノボザイムズ社製)等が好ましく挙げられる。 Commercially available endo-proteases derived from bacteria of the genus Bacillus are not particularly limited; Preferred examples include Neutrase (manufactured by Novozymes) and Neutrase (manufactured by Novozymes).
 バシラス属細菌由来のエンド型プロテアーゼの使用量は、目的とする乳タンパク質分解物の収量等に応じて適宜設定することができるが、例えば、上限値として好ましくは乳タンパク質1g当たり5000活性単位以下、4500活性単位以下、より好ましくは4000活性単位以下、3500活性単位以下、さらに好ましくは3000活性単位以下用いることができ、下限値として乳タンパク質1g当たり500活性単位以上、600活性単位以上、700活性単位以上、800活性単位以上、900活性単位以上、より好ましくは1000活性単位以上用いることができる。また、好適な範囲としては、前述の上限値と下限値の矛盾のない任意の組み合わせの範囲であってよく、好ましくは乳タンパク質1g当たり500~5000活性単位、より好ましくは乳タンパク質1g当たり1000~4000活性単位、さらに好ましくは乳タンパク質1g当たり1000~3000活性単位を用いる。
 ここで、バシラス属細菌由来のエンド型プロテアーゼの活性単位は、基質カゼインに対して、37℃、pH7で、1分間にL-チロシン1μgに相当するフォリン試液呈色物質の増加をもたらす酵素量をいう。
The amount of endo-protease derived from Bacillus bacteria can be appropriately set depending on the desired yield of milk protein decomposition product, etc., but for example, the upper limit is preferably 5000 activity units or less per 1 g of milk protein, 4500 activity units or less, more preferably 4000 activity units or less, 3500 activity units or less, still more preferably 3000 activity units or less can be used, and the lower limit is 500 activity units or more, 600 activity units or more, 700 activity units per gram of milk protein. Above, 800 or more active units, 900 or more active units, more preferably 1000 or more active units can be used. Further, a suitable range may be any combination of the above-mentioned upper and lower limits that is consistent with each other, preferably 500 to 5000 activity units per gram of milk protein, more preferably 1000 to 5000 activity units per gram of milk protein. 4000 activity units are used, more preferably 1000 to 3000 activity units per gram of milk protein.
Here, the activity unit of endo-type protease derived from bacteria of the genus Bacillus is defined as the amount of enzyme that causes an increase in the colored substance of Folin reagent corresponding to 1 μg of L-tyrosine per minute at 37°C and pH 7 against the substrate casein. say.
 パパインは、パパイヤ由来のシステインプロテアーゼである。パパインは、一種又は二種以上用いてもよい。また、市販品を用いてもよい。
 パパインの市販品としては、特に限定されないが、例えば、パパインW-40(天野エンザイム製)、精製パパイン(アサヒビール社製)等が好ましく挙げられる。
Papain is a cysteine protease derived from papaya. One or more types of papain may be used. Alternatively, commercially available products may be used.
Commercial products of papain are not particularly limited, but preferred examples include papain W-40 (manufactured by Amano Enzyme), purified papain (manufactured by Asahi Breweries), and the like.
 パパインの使用量は、目的とする乳タンパク質分解物の収量等に応じて適宜設定することができるが、例えば、上限値として好ましくは乳タンパク質1g当たり5000活性単位以下、より好ましくは4000活性単位以下、3500活性単位以下、さらに好ましくは3000活性単位以下用いることができ、下限値として乳タンパク質1g当たり500活性単位以上、600活性単位以上、700活性単位以上、800活性単位以上、900活性単位以上、より好ましくは1000活性単位以上、さらに好ましくは1500活性単位以上用いることができる。また、好適な範囲としては、前述の上限値と下限値の矛盾のない任意の組み合わせの範囲であってよく、好ましくは乳タンパク質1g当たり500~5000活性単位、より好ましくは乳タンパク質1g当たり1000~4000活性単位、さらに好ましくは乳タンパク質1g当たり1500~3000活性単位を用いる。
 ここで、パパインの活性単位は、基質カゼインに対して、38℃、pH6で、1分間にチロシン1μgに相当する波長275nmの吸収量を増加させることができる酵素量をいう。
The amount of papain used can be appropriately set depending on the desired yield of milk protein decomposition products, etc., but for example, the upper limit is preferably 5000 activity units or less, more preferably 4000 activity units or less per 1 g of milk protein. , 3500 activity units or less, more preferably 3000 activity units or less, and the lower limit is 500 activity units or more, 600 activity units or more, 700 activity units or more, 800 activity units or more, 900 activity units or more, More preferably, it can be used in an amount of 1000 or more active units, and still more preferably 1500 or more active units. Further, a suitable range may be any combination of the above-mentioned upper and lower limits that is consistent with each other, preferably 500 to 5000 activity units per gram of milk protein, more preferably 1000 to 5000 activity units per gram of milk protein. 4000 activity units are used, more preferably 1500 to 3000 activity units per gram of milk protein.
Here, the activity unit of papain refers to the amount of enzyme that can increase the amount of absorption at a wavelength of 275 nm corresponding to 1 μg of tyrosine per minute at 38° C. and pH 6 with respect to the substrate casein.
 本発明においては、微生物由来のトリプシン様エンド型プロテアーゼ、バシラス属細菌由来のエンド型プロテアーゼ、及びパパインの三種類を組み合わせて用いるが、本発明の効果を損なわない限りにおいて他のタンパク質分解酵素を用いてもよい。他のタンパク質分解酵素としては、動物由来、微生物由来、植物由来のものが挙げられるが、本発明においては動物由来のタンパク質分解酵素を実質的に用いないことが好ましい。
 ここで「実質的に用いない」とは、動物由来のプロテアーゼを全く用いないことのみを意味するものではなく、動物由来のプロテアーゼによる乳タンパク質分解活性が測定できないか、または動物由来のプロテアーゼによる乳タンパク質分解活性が測定できたとしても、前記三種類のタンパク質分解酵素の分解活性に比べて低いものであって、動物由来のプロテアーゼがプロテアーゼとして効果を奏しない程度に含有し、本発明が属する技術分野における当業者から見て無視できる程度のものであることも含む意味である。
In the present invention, a trypsin-like endoprotease derived from a microorganism, an endoprotease derived from a Bacillus bacterium, and papain are used in combination, but other proteolytic enzymes may be used as long as they do not impair the effects of the present invention. It's okay. Examples of other proteolytic enzymes include those derived from animals, microorganisms, and plants; however, in the present invention, it is preferable not to use substantially animal-derived proteolytic enzymes.
Here, "substantially not used" does not mean not only that no animal-derived protease is used at all, but also that the milk proteolytic activity of the animal-derived protease cannot be measured or that the milk protein degradation activity of the animal-derived protease is not used. Even if the proteolytic activity can be measured, it is lower than the degrading activity of the three types of proteolytic enzymes mentioned above, and the animal-derived protease is contained to the extent that it is not effective as a protease, and the technology to which the present invention belongs This also means that it is negligible from the perspective of a person skilled in the art.
 例えば、「動物由来のプロテアーゼを実質的に用いない」とは、微生物由来のトリプシン様エンド型プロテアーゼ、バシラス属細菌由来のエンド型プロテアーゼ、又はパパインの乳タンパク質分解活性を100%としたときに、動物由来のプロテアーゼの乳タンパク質分解活性が5%以下、4%以下、3%以下、2%以下、1%以下、0.5%以下、0.1%以下、0.05%以下または0.01%以下である場合には「実質的に用いない」ということができる。 For example, "substantially no animal-derived proteases are used" means that when the milk proteolytic activity of trypsin-like endoprotease derived from microorganisms, endoprotease derived from Bacillus bacteria, or papain is taken as 100%, The milk proteolytic activity of the animal-derived protease is 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, 0.5% or less, 0.1% or less, 0.05% or less, or 0. If it is less than 0.01%, it can be said that it is "substantially not used."
 本明細書において、「微生物由来」「バシラス属細菌由来」「パパイン由来」というときの「由来」とは、元来その微生物や植物がそのプロテアーゼを保持していることを意味し、採取原を意味するものではない。例えば、バシラス属細菌が産生するプロテアーゼをコードする遺伝子をエシェリヒア・コリに導入し、同遺伝子を発現させることにより製造したプロテアーゼは、バシラス属細菌「由来」である。また、「元来バシラス属細菌が保持している」というときのバシラス属細菌には、野生型のみならず、本発明に必要なプロテアーゼ活性や特異性を有するプロテアーゼを生産する機能を維持している限り、組換え体または変異体が含まれる。 In this specification, "origin" when referring to "derived from a microorganism," "derived from a Bacillus bacterium," or "derived from papain" means that the microorganism or plant originally retains the protease. It doesn't mean anything. For example, a protease produced by introducing a gene encoding a protease produced by a bacterium of the genus Bacillus into Escherichia coli and expressing the same gene is "derived from" a bacterium of the genus Bacillus. In addition, the Bacillus bacteria that are referred to as "originally possessed by Bacillus bacteria" include not only wild type bacteria, but also those that maintain the ability to produce proteases that have the protease activity and specificity required for the present invention. Recombinants or mutants are included as long as they exist.
 本発明におけるタンパク質分解工程は、タンパク質分解酵素を乳タンパク質に作用させる。
 以下に一般的な手順を説明するが、特にこれに限定されるものではない。
 原料となる乳タンパク質を水、または温湯に分散又は溶解させる。
 次いで、前記乳タンパク質液を、70~130℃で2秒間~10分間程度加熱殺菌することが、雑菌汚染による変敗防止の点から望ましい。加熱殺菌条件は、例えば85℃で10分間、90℃で6分間、121℃で1分間、130℃で2秒間等で行う。
 さらに、加熱殺菌後の乳タンパク質液を、ナトリウム型又はカリウム型陽イオン交換樹脂(好適には強酸性陽イオン交換樹脂)を用いたイオン交換法、電気透析法、限外濾過膜法、ナノ濾過膜法等で脱塩してもよい。脱塩の際には、カラム式やバッチ式の何れを採用してもよい。
 次いで、前記乳タンパク質液にアルカリ剤、または酸剤を添加し、pHを使用する加水分解酵素の至適pH、またはその付近に調整することが好ましい。本発明の製造方法に使用するアルカリ剤、または酸剤は、食品、または医薬品に許容されるものであれば、特に限定されず用いることができる。具体的には、アルカリ剤としては、水酸化ナトリウム、水酸化カリウム、炭酸カリウム等を、酸剤としては、塩酸、クエン酸、リン酸、酢酸等を例示することができる。
In the proteolytic step in the present invention, a proteolytic enzyme is allowed to act on milk proteins.
A general procedure will be explained below, but it is not particularly limited thereto.
Milk protein as a raw material is dispersed or dissolved in water or hot water.
Next, it is desirable to heat sterilize the milk protein liquid at 70 to 130° C. for about 2 seconds to 10 minutes from the viewpoint of preventing deterioration due to bacterial contamination. Heat sterilization conditions include, for example, 85°C for 10 minutes, 90°C for 6 minutes, 121°C for 1 minute, and 130°C for 2 seconds.
Furthermore, the milk protein liquid after heat sterilization is subjected to ion exchange method using a sodium type or potassium type cation exchange resin (preferably a strongly acidic cation exchange resin), electrodialysis method, ultrafiltration membrane method, or nanofiltration method. Desalination may be performed using a membrane method or the like. For desalting, either a column method or a batch method may be employed.
Next, it is preferable to add an alkaline agent or an acidic agent to the milk protein solution to adjust the pH to the optimum pH of the hydrolyzing enzyme used or around it. The alkaline agent or acid agent used in the production method of the present invention is not particularly limited as long as it is acceptable for foods or medicines. Specifically, examples of alkaline agents include sodium hydroxide, potassium hydroxide, potassium carbonate, etc., and examples of acid agents include hydrochloric acid, citric acid, phosphoric acid, acetic acid, etc.
 次に、乳タンパク質液に所定量のタンパク質分解酵素を加え、温度10~85℃で0.1~48時間程度反応を行う。
 なお、前述の三種類のタンパク質分解酵素それぞれの酵素反応は、同時に行ってもよく、別々に行ってもよい。
Next, a predetermined amount of proteolytic enzyme is added to the milk protein solution, and a reaction is carried out at a temperature of 10 to 85°C for about 0.1 to 48 hours.
Note that the enzymatic reactions of the three types of proteolytic enzymes described above may be performed simultaneously or separately.
 酵素を添加した溶液を、酵素の種類に応じて適当な温度に保持して乳タンパク質の加水分解を開始する。温度は、例えば30℃以上、40℃以上、45℃以上であってよく、60℃以下、55℃以下であってもよい。またこれらの矛盾しない任意の組み合わせであってもよい。なお、前記温度における好適な範囲としては30~60℃、望ましくは45~55℃である。加水分解反応時間は、酵素反応の分解率をモニターしながら、好ましい分解率に達するまで反応を続ける。後述する分子量に相当する分解物を得るためには、分解率は8%以上、9%以上、10%以上、11%以上、12%以上、13%以上、14%以上、15%以上であってよく、及び35%以下、34%以下、33%以下、32%以下、31%以下、30%以下、29%以下、28%以下、27%以下、24%以下、25%以下であってもよい。また、これらの矛盾しない任意の組み合わせであってもよい。なお、分解率の好適な範囲としては8~35%、10~30%、15~25%が望ましい。 The solution containing the enzyme is maintained at an appropriate temperature depending on the type of enzyme to begin hydrolysis of milk proteins. The temperature may be, for example, 30°C or higher, 40°C or higher, 45°C or higher, or 60°C or lower, or 55°C or lower. Further, any combination of these that does not contradict each other may be used. Note that the suitable temperature range is 30 to 60°C, preferably 45 to 55°C. The hydrolysis reaction time is such that the reaction is continued until a desired decomposition rate is reached while monitoring the decomposition rate of the enzymatic reaction. In order to obtain decomposition products corresponding to the molecular weights described below, the decomposition rate must be 8% or more, 9% or more, 10% or more, 11% or more, 12% or more, 13% or more, 14% or more, or 15% or more. and 35% or less, 34% or less, 33% or less, 32% or less, 31% or less, 30% or less, 29% or less, 28% or less, 27% or less, 24% or less, 25% or less. Good too. Further, any combination of these that is not contradictory may be used. Note that the preferable range of decomposition rate is 8 to 35%, 10 to 30%, and 15 to 25%.
 なお、乳タンパク質の分解率の算出方法は、ケルダール法(日本食品工業学会編、「食品分析法」、第102頁、株式会社光琳、昭和59年)により試料の全窒素量を測定し、ホルモール滴定法(満田他編、「食品工学実験書」、上巻、第547ページ、養賢堂、1970年)により試料のホルモール態窒素量を測定し、これらの測定値から分解率を次式により算出する。
 分解率(%)=ホルモール態窒素量÷全窒素量×100
The decomposition rate of milk protein is calculated by measuring the total nitrogen content of the sample using the Kjeldahl method (edited by the Japan Society of Food Industry, "Food Analysis Methods", p. 102, Korin Co., Ltd., 1982), and by measuring the total nitrogen content of the sample. The amount of formol nitrogen in the sample was measured by the titration method (edited by Mitsuda et al., "Food Engineering Experiment Book", Vol. 1, p. 547, Yokendo, 1970), and the decomposition rate was calculated from these measured values using the following formula: do.
Decomposition rate (%) = formol nitrogen amount ÷ total nitrogen amount x 100
 酵素反応の停止は、例えば、加水分解液中の酵素の失活により行われ、常法による加熱失活処理により実施することができる。加熱失活処理の加熱温度と保持時間は、使用した酵素の熱安定性を考慮し、十分に失活できる条件を適宜設定することができるが、例えば、80~130℃の温度範囲で2秒間~30分間の保持時間で行うことができる。 The enzymatic reaction is stopped, for example, by deactivating the enzyme in the hydrolysis solution, and can be carried out by heat deactivation treatment using a conventional method. The heating temperature and holding time of the heat inactivation treatment can be appropriately set to conditions that can sufficiently inactivate the enzyme, taking into consideration the thermal stability of the enzyme used. This can be done with a holding time of ~30 minutes.
 加熱失活後、常法により冷却し、そのまま利用することもでき、必要に応じて濃縮して濃縮液を得ることもできる。さらに濃縮液を乾燥し、粉末製品を得ることも可能である。また、得られた乳タンパク質分解物に対し、定法により分離、精製等の操作を行ってもよい。 After heat inactivation, it can be cooled by a conventional method and used as it is, or if necessary, it can be concentrated to obtain a concentrated liquid. Furthermore, it is also possible to dry the concentrate to obtain a powder product. Further, the obtained milk protein decomposition product may be subjected to operations such as separation and purification using conventional methods.
 乳タンパク質分解物の精製は、通常、ペプチドの精製に用いられているのと同様の手法、例えばイオン交換クロマトグラフィー、吸着クロマトグラフィー、逆相クロマトグラフィー、分配クロマトグラフィー、ゲル濾過クロマトグラフィー等の各種クロマトグラフィー、溶媒沈殿、塩析、2種の液相間での分配等の方法等を適宜組み合わせることによって、行うことができる。 Purification of milk protein digests is usually carried out using various techniques similar to those used for peptide purification, such as ion-exchange chromatography, adsorption chromatography, reversed-phase chromatography, partition chromatography, and gel filtration chromatography. This can be carried out by appropriately combining methods such as chromatography, solvent precipitation, salting out, distribution between two liquid phases, and the like.
 本発明の製造方法により得られる乳タンパク質分解物の数平均分子量は、上限値として650以下であり、640以下であり、630以下であってよく、620以下であってよく、610以下であってよく、好ましくは600以下、590以下、580以下、570以下、560以下であってよく、より好ましくは550以下、540以下、530以下であってよく、下限値として、230以上、240以上、または250以上であってよく、好ましくは260以上、270以上であってよく、より好ましくは280以上である。また、これらの矛盾しない任意の組み合わせであってもよい。
 ここで乳タンパク質分解物の平均分子量は、以下の数平均分子量の概念により求めるものである。
 数平均分子量(Number Average of Molecular Weight)は、例えば文献(社団法人高分子学会編、「高分子科学の基礎」、第116~119頁、株式会社東京化学同人、1978年)に記載されているとおり、高分子化合物の分子量の平均値を次のとおり異なる指標に基づき示すものである。
 すなわち、乳タンパク質分解物等の高分子化合物は不均一な物質であり、かつ分子量に分布があるため、乳タンパク質分解物の分子量は、物理化学的に取り扱うためには、平均分子量で示す必要があり、数平均分子量(以下、Mnと略記することがある。)は、分子の個数についての平均である。
The number average molecular weight of the milk protein decomposition product obtained by the production method of the present invention is 650 or less as an upper limit, may be 640 or less, may be 630 or less, may be 620 or less, may be 610 or less, Preferably it may be 600 or less, 590 or less, 580 or less, 570 or less, 560 or less, more preferably 550 or less, 540 or less, 530 or less, and the lower limit is 230 or more, 240 or more, or 250 or more. It may be preferably 260 or more, 270 or more, and more preferably 280 or more. Further, any combination of these that is not contradictory may be used.
The average molecular weight of the milk protein decomposition product is determined based on the concept of number average molecular weight below.
The number average of Molecular Weight is described, for example, in the literature (edited by The Society of Polymer Science, "Basics of Polymer Science", pp. 116-119, Tokyo Kagaku Dojin Co., Ltd., 1978). The average value of the molecular weight of a polymer compound is shown based on the following different indicators.
In other words, high molecular compounds such as milk protein decomposition products are heterogeneous substances and have a distribution of molecular weights, so the molecular weight of milk protein decomposition products must be expressed as an average molecular weight in order to treat them physicochemically. The number average molecular weight (hereinafter sometimes abbreviated as Mn) is the average number of molecules.
 本明細書において、乳タンパク質分解物の平均分子量は、以下の方法で測定及び算出したものをいう。すなわち、高速液体クロマトグラフィーを使用して、リハイドロキシエチル・アスパルタミド・カラム(Poly Hydroxyethyl Aspartamide Column、Poly LC社製、直径4.6mm及び長さ200mm)を用い、20mM塩化ナトリウム、50mMギ酸により溶出速度0.5mL/分で溶出する(宇井信生ら編、「タンパク質・ペプチドの高速液体クロマトグラフィー」、化学増刊第102号、第241頁、株式会社化学同人、1984年)。検出は、UV検出器(島津製作所社製)を使用して行い、GPC分析システム(島津製作所社製)によりデータ解析して数平均分子量を算出する。なお、分子量算出のための標品は、分子量が既知のタンパク質及び/又はペプチドを適宜用いればよい。 In this specification, the average molecular weight of a milk protein decomposition product is measured and calculated by the following method. That is, using high performance liquid chromatography, using a Poly Hydroxyethyl Aspartamide Column (manufactured by Poly LC, diameter 4.6 mm and length 200 mm), the elution rate was adjusted using 20 mM sodium chloride and 50 mM formic acid. Elutes at 0.5 mL/min (Nobuo Ui et al., ed., "High Performance Liquid Chromatography of Proteins and Peptides", Kagaku Special Edition No. 102, p. 241, Kagaku Dojin Co., Ltd., 1984). Detection is performed using a UV detector (manufactured by Shimadzu Corporation), and data is analyzed by a GPC analysis system (manufactured by Shimadzu Corporation) to calculate the number average molecular weight. In addition, as a sample for calculating the molecular weight, a protein and/or a peptide with a known molecular weight may be used as appropriate.
 なお、乳タンパク質分解物には、一般に製造過程において遊離アミノ酸が含まれる。  Note that milk protein decomposition products generally contain free amino acids during the manufacturing process.​
 本発明の製造方法により取得される乳タンパク質分解物は、分解度が高く低分子量のペプチドでありながら、乳化性が良好な物である。乳化性が良好であることにより、脂肪と混合した際に優れた乳化安定性を示す。
 また、本発明の製造方法により取得される乳タンパク質分解物は、熱安定性も良好である。
The milk protein decomposition product obtained by the production method of the present invention is a peptide with a high degree of decomposition and a low molecular weight, but has good emulsifying properties. Due to its good emulsifying properties, it exhibits excellent emulsion stability when mixed with fat.
Furthermore, the milk protein decomposition product obtained by the production method of the present invention also has good thermal stability.
 また、本発明の製造方法により取得される乳タンパク質分解物は、分解度が高く低分子量であるため、抗原性が低減されている。
 一般に乳タンパク質やその分解物において問題となり得る抗原としてはカゼインやβ-ラクトグロブリン等が挙げられるところ、本発明の製造方法により取得される乳タンパク質分解物ではこれらに対する抗原性が低い。具体的には、カゼインの抗原残存活性が好ましくは2ppm以下、より好ましくは1.5ppm以下である。また、β-ラクトグロブリンの抗原残存活性が好ましくは150ppm以下、より好ましくは100ppm以下、さらに好ましくは75ppm以下である。
In addition, the milk protein decomposition product obtained by the production method of the present invention has a high degree of decomposition and a low molecular weight, and therefore has reduced antigenicity.
In general, casein, β-lactoglobulin, and the like are examples of antigens that can be a problem with milk proteins and their decomposition products, but the milk protein decomposition products obtained by the production method of the present invention have low antigenicity against these. Specifically, the antigen residual activity of casein is preferably 2 ppm or less, more preferably 1.5 ppm or less. Further, the antigen residual activity of β-lactoglobulin is preferably 150 ppm or less, more preferably 100 ppm or less, and still more preferably 75 ppm or less.
 また、本発明の製造方法により取得される乳タンパク質分解物は、動物由来の乳タンパク質分解酵素を用いずとも優れた乳タンパク質分解物を製造できるため、ハラル食品に認定される基準に適合した製品へ好適に利用できる。 In addition, the milk protein decomposition product obtained by the production method of the present invention can be produced as an excellent milk protein decomposition product without using animal-derived milk protein degrading enzymes, so it is a product that meets the standards to be certified as a halal food. It can be used suitably.
 本発明の製造方法により取得される乳タンパク質分解物は、医薬品、飲食品、飼料等に配合して使用することができる。本発明の製造方法により取得される乳タンパク質分解物は、乳由来の原料を用いているため、生体への安全性が高く、長期間、連続的な摂取にも適している。加えて、生体材料として比較的安価な乳由来の原料から生産しているため、安定して簡便に、しかも大量に製造することができ、需要者に対して安価に提供することも可能である。 The milk protein decomposition product obtained by the production method of the present invention can be used by blending it into medicines, food and drink products, feeds, etc. Since the milk protein decomposition product obtained by the production method of the present invention uses raw materials derived from milk, it is highly safe for living organisms and is suitable for continuous intake over a long period of time. In addition, because it is produced from milk-derived raw materials, which are relatively inexpensive as biomaterials, it can be produced stably and easily in large quantities, and it can also be provided to users at low cost. .
 本発明の製造方法により取得される乳タンパク質分解物は、飲食品に好ましく含有させることができる。なお、飲食品には、飲食品や医薬品に添加する添加物の態様でも含まれる。かかる態様としては、例えば、搾乳された母乳や調製乳に添加する添加物が挙げられ、添加後の乳を新生児や乳児に摂取させることが想定される。
 飲食品は、通常は経口摂取されるものであるが、これに限られず、例えば経鼻摂取されるもの、胃瘻や腸瘻により摂取されるものでもよい。例えば、新生児や乳児に対し、後述の調製乳や、乳タンパク質分解物を添加した母乳を、経鼻胃栄養チューブ等によって摂取させることが想定される。
The milk protein decomposition product obtained by the production method of the present invention can be preferably included in foods and drinks. Note that foods and drinks also include the form of additives added to foods and drinks and medicines. Such embodiments include, for example, additives added to expressed breast milk or formula milk, and it is assumed that newborns and infants ingest the added milk.
Foods and drinks are usually ingested orally, but are not limited to this, and may be ingested nasally, or through a gastrostomy or intestinal fistula. For example, it is envisaged that newborns and infants will be fed formula milk, which will be described later, or breast milk to which milk protein decomposition products have been added, through a nasogastric feeding tube or the like.
 飲食品としては、液状、ペースト状、ゲル状固体、粉末等の形態を問わず、例えば、錠菓;パン、マカロニ、スパゲッティ、めん類、ケーキミックス、から揚げ粉、パン粉等の小麦粉製品;即席めん、カップめん、レトルト・調理食品、調理缶詰め、電子レンジ食品、即席スープ・シチュー、即席みそ汁・吸い物、スープ缶詰め、フリーズ・ドライ食品、その他の即席食品等の即席食品類;農産缶詰め、果実缶詰め、ジャム・マーマレード類、漬物、煮豆類、農産乾物類、シリアル(穀物加工品)等の農産加工品;水産缶詰め、魚肉ハム・ソーセージ、水産練り製品、水産珍味類、つくだ煮類等の水産加工品;畜産缶詰め・ペースト類、畜肉ハム・ソーセージ等の畜産加工品;加工乳、乳飲料、ヨーグルト類、乳酸菌飲料類、チーズ、アイスクリーム類、クリーム、その他の乳製品等の乳・乳製品;バター、マーガリン類、植物油等の油脂類;しょうゆ、みそ、ソース類、トマト加工調味料、みりん類、食酢類等の基礎調味料;調理ミックス、カレーの素類、たれ類、ドレッシング類、めんつゆ類、スパイス類、その他の複合調味料等の複合調味料・食品類;素材冷凍食品、半調理冷凍食品、調理済冷凍食品等の冷凍食品;キャラメル、キャンディー、チューインガム、チョコレート、クッキー、ビスケット、ケーキ、パイ、スナック、クラッカー、和菓子、米菓子、豆菓子、デザート菓子、ゼリー、その他の菓子などの菓子類;炭酸飲料、天然果汁、果汁飲料、果汁入り清涼飲料、果肉飲料、果粒入り果実飲料、野菜系飲料、豆乳、豆乳飲料、コーヒー飲料、お茶飲料、粉末飲料、濃縮飲料、スポーツ飲料、栄養飲料、アルコール飲料、その他の嗜好飲料等の嗜好飲料類、ベビーフード、ふりかけ、お茶漬けのり等のその他の市販食品等;調製乳(粉乳、液状乳等を含む)、流動食、サプリメント等の栄養組成物;機能性食品(特定保健用食品、栄養機能食品)等が挙げられる。 Foods and beverages may be in the form of liquids, pastes, solid gels, powders, etc., such as tablets; bread, macaroni, spaghetti, noodles, cake mixes, flour products such as fried flour and bread crumbs; instant noodles; instant foods such as cup noodles, retort/cooked foods, cooked canned foods, microwave foods, instant soups/stews, instant miso soup/suimono, canned soups, freeze/dried foods, and other instant foods; canned agricultural products, canned fruits, and jams.・Processed agricultural products such as marmalade, pickles, boiled beans, dried agricultural products, and cereals (processed grain products); Processed marine products such as canned seafood, fish ham/sausages, fish paste products, seafood delicacies, and boiled fish; Canned livestock products - Processed livestock products such as pastes, meat hams and sausages; Milk and dairy products such as processed milk, milk drinks, yogurts, lactic acid bacteria drinks, cheese, ice creams, creams, and other dairy products; Butter, margarine , fats and oils such as vegetable oil; basic seasonings such as soy sauce, miso, sauces, processed tomato seasonings, mirin, vinegars; cooking mixes, curry ingredients, sauces, dressings, noodle soups, spices, Complex seasonings and foods such as other complex seasonings; frozen foods such as raw frozen foods, semi-cooked frozen foods, and cooked frozen foods; caramels, candies, chewing gums, chocolates, cookies, biscuits, cakes, pies, snacks, Confectionery such as crackers, Japanese sweets, rice sweets, bean sweets, dessert sweets, jellies, and other sweets; carbonated drinks, natural fruit juices, fruit juice drinks, soft drinks with fruit juice, pulp drinks, fruit drinks with fruit granules, vegetable drinks, Soy milk, soy milk drinks, coffee drinks, tea drinks, powdered drinks, concentrated drinks, sports drinks, nutritional drinks, alcoholic drinks, other drinks such as other drinks, baby food, furikake, other commercially available foods such as ochazuke nori, etc. Nutrient compositions such as formula milk (including powdered milk, liquid milk, etc.), liquid foods, and supplements; Functional foods (foods for specified health uses, foods with nutritional function functions), and the like.
 これらのうち、栄養組成物が好ましく挙げられる。
 本発明において、「栄養組成物」は、飲食品の一態様として特に限定されないが、好ましくは調製乳、流動食、サプリメント等であり、より好ましくは調製乳である。摂取対象は、乳児、幼児、小児、成人を問わないが、好ましくは乳児及び幼児である。
 調製乳には、調製粉乳、調製液状乳が含まれる。
 調製粉乳は、乳および乳製品の成分規格等に関する省令(乳等省令)において、「生乳、牛乳、特別牛乳、またはこれらを原料として製造した食品を加工し、または主要原料とし、乳幼児に必要な栄養分を加え粉末状にしたもの」として定義される。
 調製液状乳は、前記省令において、「生乳、牛乳、特別牛乳、またはこれらを原料として製造した食品を加工し、または主要原料とし、乳幼児に必要な栄養分を加え液状にしたもの」として定義される。
 また、調製乳は、各種の蛋白質、油脂、炭水化物、ミネラル類、ビタミン類等の栄養成分が配合されたものであって、粉末状又は液状に加工されたものも含まれる。
 また、調製乳にはさらに、健康増進法で規定される特別用途食品における「乳児用調製粉乳」、「乳児用調製液状乳」「妊産婦、授乳婦用粉乳」が含まれ、幼児向け調製粉乳、成人用栄養粉末、高齢者用栄養粉末等の態様も含まれる。
Among these, nutritional compositions are preferred.
In the present invention, the "nutritional composition" is not particularly limited as an aspect of food or drink, but preferably includes formula milk, liquid food, supplements, etc., and more preferably formula milk. Ingestion targets may be infants, toddlers, children, or adults, but infants and young children are preferred.
Formulated milk includes powdered milk and liquid milk.
According to the Ministerial Ordinance Concerning Ingredient Standards for Milk and Dairy Products (Ministerial Ordinance on Milk, etc.), infant formula is defined as ``processed raw milk, cow's milk, special milk, or foods manufactured using these as raw materials, or as a main ingredient, It is defined as a powdered product with added nutrients.
Prepared liquid milk is defined in the above ministerial ordinance as "a product made by processing raw milk, cow's milk, special milk, or food products made from these as raw materials, or by adding nutrients necessary for infants and infants to liquid form as a main ingredient." .
In addition, formula milk contains nutritional ingredients such as various proteins, fats and oils, carbohydrates, minerals, and vitamins, and includes those processed into powder or liquid form.
In addition, formula milk further includes ``infant formula'', ``infant formula liquid milk'', and ``powdered milk for pregnant women and lactating mothers'', which are foods for special dietary uses stipulated by the Health Promotion Act. Embodiments such as nutritional powder for adults and nutritional powder for the elderly are also included.
 サプリメントの形態とする場合は、散剤、顆粒剤、錠剤、カプセル剤等の固形製剤;溶液剤、シロップ剤、懸濁剤、乳剤等の液剤;等に製剤化することができる。かかる製剤化に際しては、後述する医薬品の製剤化に係る成分、担体、及び方法の説明に準ずることができる。 When in the form of a supplement, it can be formulated into solid preparations such as powders, granules, tablets, and capsules; liquid preparations such as solutions, syrups, suspensions, and emulsions; and the like. Such formulation can be carried out in accordance with the explanations of components, carriers, and methods for formulating pharmaceuticals, which will be described later.
 また、飲食品の一態様として飼料とすることもできる。飼料としては、ペットフード、家畜飼料、養魚飼料等が挙げられる。
 飼料の形態としては特に制限されず、例えば、トウモロコシ、小麦、大麦、ライ麦、マイロ等の穀類;大豆油粕、ナタネ油粕、ヤシ油粕、アマニ油粕等の植物性油粕類;フスマ、麦糠、米糠、脱脂米糠等の糠類;コーングルテンミール、コーンジャムミール等の製造粕類;魚粉、脱脂粉乳、ホエイ、イエローグリース、タロー等の動物性飼料類;トルラ酵母、ビール酵母等の酵母類;第三リン酸カルシウム、炭酸カルシウム等の鉱物質飼料;油脂類;単体アミノ酸;糖類等を含有するものであってよい。
Moreover, it can also be used as feed as one aspect of food and drink products. Examples of the feed include pet food, livestock feed, and fish feed.
The form of the feed is not particularly limited and includes, for example, grains such as corn, wheat, barley, rye, and milo; vegetable oil cakes such as soybean oil meal, rapeseed oil meal, coconut oil meal, and linseed oil meal; bran, wheat bran, rice bran, Bran such as defatted rice bran; Manufactured lees such as corn gluten meal and corn jam meal; Animal feed such as fish meal, skim milk powder, whey, yellow grease, and tallow; Yeast such as Torula yeast and brewer's yeast; It may contain mineral feeds such as calcium phosphate and calcium carbonate; oils and fats; simple amino acids; sugars, etc.
 本発明の製造方法により取得される乳タンパク質分解物は、有効成分として医薬品中に含有させてもよい。
 医薬品の形態としては、投与方法に応じて、適宜所望の剤形に製剤化することができる。例えば、経口投与の場合、散剤、顆粒剤、錠剤、カプセル剤等の固形製剤;溶液剤、シロップ剤、懸濁剤、乳剤等の液剤等に製剤化することができる。また、非経口投与の場合、座剤、軟膏剤、注射剤等に製剤化することができる。
 製剤化に際しては、通常製剤化に用いられている賦形剤、pH調整剤、着色剤、矯味剤等の成分を用いることができる。また、他の薬効成分や、公知の又は将来的に見出されるビフィドバクテリウム属細菌に対するプレバイオティクスや、他の細菌に対するプレバイオティクスなどを併用することも可能である。
 加えて、製剤化は剤形に応じて適宜公知の方法により実施できる。製剤化に際しては、適宜、製剤担体を配合して製剤化してもよい。
The milk protein decomposition product obtained by the production method of the present invention may be included in pharmaceuticals as an active ingredient.
The pharmaceutical form can be appropriately formulated into a desired dosage form depending on the administration method. For example, in the case of oral administration, it can be formulated into solid preparations such as powders, granules, tablets, and capsules; liquid preparations such as solutions, syrups, suspensions, and emulsions. In the case of parenteral administration, it can be formulated into suppositories, ointments, injections, etc.
In formulation, components such as excipients, pH adjusters, coloring agents, and flavoring agents that are commonly used in formulation can be used. It is also possible to use other medicinal ingredients, prebiotics against Bifidobacterium bacteria that are known or will be discovered in the future, prebiotics against other bacteria, and the like.
In addition, formulation can be carried out by appropriately known methods depending on the dosage form. When formulating, a pharmaceutical carrier may be added as appropriate.
 賦形剤としては、例えば、乳糖、白糖、ブドウ糖、マンニット、ソルビット等の糖誘導体;トウモロコシデンプン、馬鈴薯デンプン、α-デンプン、デキストリン、カルボキシメチルデンプン等のデンプン誘導体;結晶セルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、カルボキシメチルセルロース、カルボキシメチルセルロースカルシウム等のセルロース誘導体;アラビアゴム;デキストラン;プルラン;軽質無水珪酸、合成珪酸アルミニウム、メタ珪酸アルミン酸マグネシウム等の珪酸塩誘導体;リン酸カルシウム等のリン酸塩誘導体;炭酸カルシウム等の炭酸塩誘導体;硫酸カルシウム等の硫酸塩誘導体等が挙げられる。 Examples of excipients include sugar derivatives such as lactose, sucrose, glucose, mannitol, and sorbitol; starch derivatives such as corn starch, potato starch, α-starch, dextrin, and carboxymethyl starch; crystalline cellulose, hydroxypropyl cellulose, Cellulose derivatives such as hydroxypropyl methylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium; gum arabic; dextran; pullulan; silicate derivatives such as light silicic anhydride, synthetic aluminum silicate, magnesium aluminate metasilicate; phosphate derivatives such as calcium phosphate; carbonic acid Examples include carbonate derivatives such as calcium; sulfate derivatives such as calcium sulfate.
 結合剤としては、例えば、上記賦形剤の他、ゼラチン;ポリビニルピロリドン;マクロゴール等が挙げられる。 Examples of the binder include, in addition to the excipients mentioned above, gelatin; polyvinylpyrrolidone; macrogol, and the like.
 崩壊剤としては、例えば、上記賦形剤の他、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、架橋ポリビニルピロリドン等の化学修飾されたデンプン又はセルロース誘導体等が挙げられる。 Examples of the disintegrant include, in addition to the above excipients, chemically modified starch or cellulose derivatives such as croscarmellose sodium, sodium carboxymethyl starch, and crosslinked polyvinylpyrrolidone.
 滑沢剤としては、例えば、タルク;ステアリン酸;ステアリン酸カルシウム、ステアリン酸マグネシウム等のステアリン酸金属塩;コロイドシリカ;ビーガム、ゲイロウ等のワックス類;硼酸;グリコール;フマル酸、アジピン酸等のカルボン酸類;安息香酸ナトリウム等のカルボン酸ナトリウム塩;硫酸ナトリウム等の硫酸塩類;ロイシン;ラウリル硫酸ナトリウム、ラウリル硫酸マグネシウム等のラウリル硫酸塩;無水珪酸、珪酸水和物等の珪酸類;デンプン誘導体等が挙げられる。 Examples of lubricants include talc; stearic acid; stearic acid metal salts such as calcium stearate and magnesium stearate; colloidal silica; waxes such as vegum and gay wax; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid. ; carboxylic acid sodium salts such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids such as silicic anhydride and silicic acid hydrate; starch derivatives, etc. It will be done.
 安定剤としては、例えば、メチルパラベン、プロピルパラベン等のパラオキシ安息香酸エステル類;クロロブタノール、ベンジルアルコール、フェニルエチルアルコール等のアルコール類;塩化ベンザルコニウム;無水酢酸;ソルビン酸等が挙げられる。 Examples of the stabilizer include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol, and phenylethyl alcohol; benzalkonium chloride; acetic anhydride; and sorbic acid.
 矯味矯臭剤としては、例えば、甘味料、酸味料、香料等が挙げられる。
 なお、経口投与用の液剤の場合に使用する担体としては、水等の溶剤等が挙げられる。
Examples of flavoring agents include sweeteners, acidulants, fragrances, and the like.
In addition, examples of carriers used in the case of liquid preparations for oral administration include solvents such as water.
 以下、実施例により、本発明をさらに具体的に説明するが、本発明はその要旨を超えない限り、これらの実施例に限定されるものではない。 Hereinafter, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited to these Examples unless the gist thereof is exceeded.
<試験例1> 酵素分解による乳タンパク質分解物の製造1
(1)ホエイの酵素分解
 ホエイタンパク質に種々のプロテアーゼを作用させて乳タンパク質分解物を製造した。具体的には、ウシの乳由来のホエイタンパク質(Milei80、ミライ社製)50gに水450gを加えてよく分散させ、水酸化ナトリウムを添加して溶液のpHを9に調整し、溶液の温度を約50℃に調整した。そこに表1に示す酵素を所定量添加して、分解反応を開始した。5時間後に溶液を85℃で10分間加熱して酵素を失活させて酵素反応を停止し、5℃に冷却した。この分解液を濃縮後凍結乾燥し、乳タンパク質分解物の凍結乾燥品を得た。
<Test Example 1> Production of milk protein decomposition product by enzymatic degradation 1
(1) Enzymatic decomposition of whey Various proteases were allowed to act on whey protein to produce milk protein decomposition products. Specifically, 450 g of water was added to 50 g of bovine milk-derived whey protein (Milei 80, manufactured by Mirai), and the solution was well dispersed. Sodium hydroxide was added to adjust the pH of the solution to 9, and the temperature of the solution was adjusted. The temperature was adjusted to about 50°C. A predetermined amount of the enzyme shown in Table 1 was added thereto to start the decomposition reaction. After 5 hours, the solution was heated at 85°C for 10 minutes to inactivate the enzyme to stop the enzyme reaction, and then cooled to 5°C. This decomposition solution was concentrated and freeze-dried to obtain a freeze-dried milk protein decomposition product.
(2)乳タンパク質分解物の分子量の測定
 得られた乳タンパク質分解物について、以下の条件で高速液体クロマトグラフィー(HPLC)を行い、分子量分布を測定した。
 カラム:ポリハイドロキシエチル・アスパルタミド・カラム(Poly Hydroxyethyl Aspartamide Column、Poly LC社製、直径4.6mm及び長さ200mm)
 移動相:20mM 塩化ナトリウム及び50mMギ酸を含む水溶液
 溶出速度:0.5mL/min
 検出:UV検出器(島津製作所社製)
 解析:GPC分析システム(島津製作所社製)を使用する。
 得られたHPLCチャートのピーク面積から、〔各分子量範囲の割合(%)〕=〔分子量分布における各分子量範囲の面積/分子量分布における乳タンパク質分解物の全面積(全エリア)〕に基づき、分子量を算出した。数平均分子量及び重量平均分子量を、表1に合わせて示す。
(2) Measurement of molecular weight of milk protein decomposition product The obtained milk protein decomposition product was subjected to high performance liquid chromatography (HPLC) under the following conditions to measure the molecular weight distribution.
Column: Poly Hydroxyethyl Aspartamide Column (Poly Hydroxyethyl Aspartamide Column, manufactured by Poly LC, diameter 4.6 mm and length 200 mm)
Mobile phase: Aqueous solution containing 20mM sodium chloride and 50mM formic acid Elution rate: 0.5mL/min
Detection: UV detector (manufactured by Shimadzu Corporation)
Analysis: Use a GPC analysis system (manufactured by Shimadzu Corporation).
From the peak area of the obtained HPLC chart, the molecular weight is determined based on [ratio (%) of each molecular weight range] = [area of each molecular weight range in the molecular weight distribution/total area (total area) of milk protein decomposition products in the molecular weight distribution]. was calculated. The number average molecular weight and weight average molecular weight are also shown in Table 1.
(3)乳タンパク質分解物の分解率の測定
 乳タンパク質分解物の分解の程度(分解率)をホルモール滴定法により測定した。具体的には、試料粉末を10%w/wの濃度で脱イオン水に溶解し、溶解液4mLに脱イオン水30mLを加え、スターラーで撹拌しながら、pHメーターを用いて0.1M水酸化ナトリウム溶液又は0.1M塩酸溶液を滴下して、pHを6.80に調整した。これに、pH8.0に調整した37%ホルマリン溶液5mLを加えた後、0.1M水酸化ナトリウム溶液で滴定し、pH7.90とした(xmL)。それと同時に、糖度計を用いて、乳タンパク質分解物溶液のBrix値(25℃)を測定した(z%)。
 上記測定値をもとに下記計算式にて乳タンパク質分解物の分解率を算出し、表1に合わせて示す。
 分解率(%)=ホルモール態窒素量÷全窒素量×100
 ホルモール態窒素量(mgN/dL)=1.4×x×f(水酸化ナトリウムの力価)×100/4
 全窒素量(mgN/dL)=z×0.7×1000/6.38
(3) Measurement of decomposition rate of milk protein decomposition product The degree of decomposition (degradation rate) of milk protein decomposition product was measured by formol titration method. Specifically, the sample powder was dissolved in deionized water at a concentration of 10% w/w, 30 mL of deionized water was added to 4 mL of the solution, and 0.1M hydroxide was added using a pH meter while stirring with a stirrer. The pH was adjusted to 6.80 by dropping sodium solution or 0.1M hydrochloric acid solution. After adding 5 mL of 37% formalin solution adjusted to pH 8.0, the mixture was titrated with 0.1 M sodium hydroxide solution to adjust the pH to 7.90 (x mL). At the same time, the Brix value (25° C.) of the milk protein decomposition solution was measured using a saccharometer (z%).
Based on the above measurement values, the decomposition rate of the milk protein decomposition product was calculated using the following formula, and is shown in Table 1.
Decomposition rate (%) = formol nitrogen amount ÷ total nitrogen amount x 100
Amount of formol nitrogen (mgN/dL) = 1.4 x x x f (potency of sodium hydroxide) x 100/4
Total nitrogen amount (mgN/dL) = z x 0.7 x 1000/6.38
(4)乳タンパク質分解物の乳化安定性の評価
 乳タンパク質分解物を水及び油脂と混合したときの乳化安定性を評価した。具体的には、試料粉末10gを脱イオン水150mLに溶解後、大豆油(富士フィルム和光純薬社製)100gを添加し、均質バルブを通過させるホモジナイザー(T.K. HOMOMIXER MARK II、(旧)特殊機化工業(株)、(現)プライミクス(株))を用いて5000rpmの圧力で乳化した。得られた乳化液をメスシリンダーに入れて24時間室温で保存した後、油層、乳化層、及び水層の各高さを測定し、液全体に対する割合を算出した。また、保存後の乳化液を目視で観察し、油脂の分離がない場合を〇、若干の分離がある場合を△、分離がある場合を×として評価した。結果を表1に合わせて示す。
(4) Evaluation of emulsion stability of milk protein decomposition product Emulsion stability when milk protein decomposition product was mixed with water and fats and oils was evaluated. Specifically, 10 g of sample powder was dissolved in 150 mL of deionized water, 100 g of soybean oil (manufactured by Fuji Film Wako Pure Chemical Industries, Ltd.) was added, and the mixture was passed through a homogenizer (T.K. ) Emulsified at a pressure of 5000 rpm using Tokushu Kika Kogyo Co., Ltd. (currently Primix Co., Ltd.). The resulting emulsion was placed in a graduated cylinder and stored at room temperature for 24 hours, and then the heights of the oil layer, emulsion layer, and water layer were measured, and the ratio to the entire liquid was calculated. In addition, the emulsion after storage was visually observed and evaluated as ◯ if there was no separation of oil or fat, △ if there was some separation, and × if there was separation. The results are also shown in Table 1.
(5)熱安定性の評価
 乳タンパク質分解物の熱安定性をレトルト殺菌試験にて評価した。具体的には、試料粉末を5%w/wの濃度で脱イオン水に溶解した溶解液200mLをレトルトパウチに封入し、高温高圧調理殺菌装置(RCS-60/10SPXTG-FAM)にてF値が4相当の加熱殺菌(130℃、90秒、0.3MPa)を行った。加熱殺菌後の溶液を目視にて観察し、析出や沈殿の有無を確認した。析出や沈殿がない場合を〇、ある場合を×として評価した。結果を表1に合わせて示す。
(5) Evaluation of thermal stability The thermal stability of the milk protein decomposition product was evaluated by a retort sterilization test. Specifically, 200 mL of a solution obtained by dissolving the sample powder in deionized water at a concentration of 5% w/w was sealed in a retort pouch, and the F value was determined using a high temperature and high pressure cooking sterilizer (RCS-60/10SPXTG-FAM). Heat sterilization equivalent to 4 (130° C., 90 seconds, 0.3 MPa) was performed. The solution after heat sterilization was visually observed to confirm the presence or absence of precipitation or precipitation. The case where there was no precipitation or precipitation was evaluated as 〇, and the case where it was evaluated as ×. The results are also shown in Table 1.
(6)抗原性の評価
 乳タンパク質分解物の抗原性を評価した。具体的には、モリナガFASPEKエライザII(森永生科学研究所社製)を用い、試料粉末をキットの検体希釈液Iで20倍に希釈し、希釈液中の総ペプチド濃度が1~50ng/mLになるように調製した。希釈液を1次抗体が固定されたプラスチックウェルに100μLずつ注ぎいれ、1時間インキュベーションした。プラスチックウェルを調製済み洗浄液で洗浄した後、酵素標識抗体を30分間反応させた。なお、検出対象はカゼイン及びβ-ラクトグロブリンの配列にそれぞれ含まれるエピトープとした。その後、調製済み洗浄液で洗浄し、酵素基質溶液を添加して反応させ、反応停止液で反応を停止させた。反応停止後、30分以内に主波長450nm、副波長620nmで吸光度を測定した。測定した吸光度は、同時に測定して作成した検量線に当てはめて、検体希釈液中総タンパク質濃度を求め、さらに、希釈倍率を乗じて試料中の抗原残存活性を求めた。抗原残存活性をそれぞれ以下の基準で3段階評価した。結果を表1に合わせて示す。
 カゼイン;
  ○:2ppm以下(抗原性なし)
  △:2~50ppm(やや抗原性あり)
  ×:50ppm以上(抗原性あり)
 β-ラクトグロブリン;
  ○:150ppm以下(抗原性なし)
  △:150~2000ppm(やや抗原性あり)
  ×:2000ppm以上(抗原性あり)
(6) Evaluation of antigenicity The antigenicity of the milk protein decomposition product was evaluated. Specifically, using Morinaga FASPEK Elizer II (manufactured by Morinaga Bioscience Institute), the sample powder was diluted 20 times with sample diluent I from the kit, and the total peptide concentration in the diluted solution was 1 to 50 ng/mL. It was prepared so that 100 μL of the diluted solution was poured into each plastic well on which the primary antibody had been immobilized, and incubated for 1 hour. After washing the plastic well with the prepared washing solution, the enzyme-labeled antibody was reacted for 30 minutes. The detection targets were epitopes contained in the sequences of casein and β-lactoglobulin, respectively. Thereafter, it was washed with a prepared washing solution, an enzyme substrate solution was added to react, and the reaction was stopped with a reaction stop solution. After the reaction was stopped, the absorbance was measured at a main wavelength of 450 nm and a sub wavelength of 620 nm within 30 minutes. The measured absorbance was applied to a calibration curve prepared by measuring at the same time to determine the total protein concentration in the sample diluted solution, and further multiplied by the dilution factor to determine the residual antigen activity in the sample. Antigen residual activity was evaluated in three stages based on the following criteria. The results are also shown in Table 1.
casein;
○: 2 ppm or less (no antigenicity)
△: 2 to 50 ppm (slightly antigenic)
×: 50 ppm or more (antigenic)
β-lactoglobulin;
○: 150 ppm or less (no antigenicity)
△: 150-2000ppm (slightly antigenic)
×: 2000 ppm or more (antigenic)
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
 表1の結果から、本発明の製造方法で調製した乳タンパク質分解物は、高い分解率で低分子量にまで分解されながらも、油脂や水の分離が少なく乳化安定性が高いことが分かる。また、熱安定性及び抗原性にも優れることがわかる。 From the results in Table 1, it can be seen that the milk protein decomposition product prepared by the production method of the present invention is degraded to a low molecular weight with a high decomposition rate, but has high emulsion stability with little separation of fats and oils and water. It is also found that it has excellent thermal stability and antigenicity.
<試験例2> 酵素分解による乳タンパク質分解物の製造2
 表2に示す酵素及びその使用量にて、試験例1と同様に乳タンパク質分解物を製造し、分子量測定、分解率の測定、乳化安定性の評価、熱安定性の評価、及び抗原性の評価を行った。結果を表2に合わせて示す。
 本発明の製造方法で調製した乳タンパク質分解物は、高い分解率で低分子量にまで分解されながらも、油脂や水の分離が少なく乳化安定性が高いことが分かる。また、熱安定性及び抗原性にも優れることがわかる。
<Test Example 2> Production of milk protein decomposition product by enzymatic degradation 2
A milk protein decomposition product was produced in the same manner as in Test Example 1 using the enzymes and their usage amounts shown in Table 2, and the molecular weight measurement, degradation rate measurement, emulsion stability evaluation, thermal stability evaluation, and antigenicity were determined. We conducted an evaluation. The results are also shown in Table 2.
It can be seen that although the milk protein decomposition product prepared by the production method of the present invention is decomposed to a low molecular weight with a high decomposition rate, there is little separation of fats and water from oil and water, and the emulsion stability is high. It is also found that it has excellent thermal stability and antigenicity.
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
<試験例3> 酵素分解による乳タンパク質分解物の製造3
 表3に示す酵素及びその使用量にて、試験例1と同様に乳タンパク質分解物を製造し、分子量測定、分解率の測定、及び乳化安定性の評価を行った。結果を表3に合わせて示す。
 本発明の製造方法で調製した乳タンパク質分解物は、高い分解率で低分子量にまで分解されながらも、油脂や水の分離が少なく乳化安定性が高いことが分かる。
<Test Example 3> Production of milk protein decomposition product by enzymatic degradation 3
A milk protein decomposition product was produced in the same manner as in Test Example 1 using the enzymes and their usage amounts shown in Table 3, and the molecular weight, decomposition rate, and emulsion stability were evaluated. The results are also shown in Table 3.
It can be seen that although the milk protein decomposition product prepared by the production method of the present invention is decomposed to a low molecular weight with a high decomposition rate, there is little separation of fats and water from oil and water, and the emulsion stability is high.
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000003
<試験例4> 酵素分解による乳タンパク質分解物の製造3
 表4に示す酵素及びその使用量にて、試験例1と同様に乳タンパク質分解物を製造し、分子量測定、分解率の測定、及び乳化安定性の評価を行った。結果を表3に合わせて示す。
 本発明の製造方法で調製した乳タンパク質分解物は、高い分解率で低分子量にまで分解されながらも、油脂や水の分離が少なく乳化安定性が高いことが分かる。
<Test Example 4> Production of milk protein decomposition product by enzymatic degradation 3
Milk protein decomposition products were produced in the same manner as in Test Example 1 using the enzymes and their usage amounts shown in Table 4, and the molecular weight, decomposition rate, and emulsion stability were evaluated. The results are also shown in Table 3.
It can be seen that although the milk protein decomposition product prepared by the production method of the present invention is decomposed to a low molecular weight with a high decomposition rate, there is little separation of fats and water from oil and water, and the emulsion stability is high.
Figure JPOXMLDOC01-appb-T000004
Figure JPOXMLDOC01-appb-T000004
 本発明は、医薬品、飲食品、飼料等の分野で有用である。 The present invention is useful in the fields of pharmaceuticals, food and drink, feed, etc.

Claims (4)

  1.  乳タンパク質分解物の製造方法であって、
     前記乳タンパク質にタンパク質分解酵素を作用させるタンパク質分解工程を含み、
     前記タンパク質分解酵素が、微生物由来のトリプシン様エンド型プロテアーゼ、バシラス属細菌由来のエンド型プロテアーゼ、及びパパインを含み、
     前記乳タンパク質分解物の数平均分子量が650以下である、製造方法。
    A method for producing a milk protein decomposition product, the method comprising:
    comprising a proteolytic step of causing a proteolytic enzyme to act on the milk protein,
    The proteolytic enzyme includes a trypsin-like endoprotease derived from a microorganism, an endoprotease derived from a Bacillus bacterium, and papain,
    The production method, wherein the milk protein decomposition product has a number average molecular weight of 650 or less.
  2.  前記乳タンパク質がホエイタンパク質である、請求項1に記載の製造方法。 The manufacturing method according to claim 1, wherein the milk protein is whey protein.
  3.  前記微生物がフザリウム属細菌である、請求項1又は2に記載の製造方法。 The manufacturing method according to claim 1 or 2, wherein the microorganism is a Fusarium bacterium.
  4.  前記タンパク質分解酵素が、動物由来のプロテアーゼを実質的に含まない、請求項1~3のいずれか一項に記載の製造方法。
     
    The production method according to any one of claims 1 to 3, wherein the proteolytic enzyme is substantially free of animal-derived proteases.
PCT/JP2023/012550 2022-03-30 2023-03-28 Method for producing milk protein degradation product WO2023190529A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-057221 2022-03-30
JP2022057221 2022-03-30

Publications (1)

Publication Number Publication Date
WO2023190529A1 true WO2023190529A1 (en) 2023-10-05

Family

ID=88201750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/012550 WO2023190529A1 (en) 2022-03-30 2023-03-28 Method for producing milk protein degradation product

Country Status (1)

Country Link
WO (1) WO2023190529A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07203844A (en) * 1994-01-12 1995-08-08 Morinaga Milk Ind Co Ltd Production of whey protein hydrolyzate excellent in emulsifiability and thermal stability and antiallergic modified milk using the same whey protein hydrolyzate
JP2012522498A (en) * 2009-04-02 2012-09-27 ノボザイムス アクティーゼルスカブ Milk-derived protein hydrolyzate
JP2013544499A (en) * 2010-10-01 2013-12-19 ノボザイムス アクティーゼルスカブ Polypeptide having endopeptidase activity and polynucleotide encoding the same
US20140004152A1 (en) * 2010-10-01 2014-01-02 Nectec S.A. Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof
WO2020239998A1 (en) * 2019-05-29 2020-12-03 Arla Foods Amba Palatable extensively hydrolysed whey protein hydrolysates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07203844A (en) * 1994-01-12 1995-08-08 Morinaga Milk Ind Co Ltd Production of whey protein hydrolyzate excellent in emulsifiability and thermal stability and antiallergic modified milk using the same whey protein hydrolyzate
JP2012522498A (en) * 2009-04-02 2012-09-27 ノボザイムス アクティーゼルスカブ Milk-derived protein hydrolyzate
JP2013544499A (en) * 2010-10-01 2013-12-19 ノボザイムス アクティーゼルスカブ Polypeptide having endopeptidase activity and polynucleotide encoding the same
US20140004152A1 (en) * 2010-10-01 2014-01-02 Nectec S.A. Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof
WO2020239998A1 (en) * 2019-05-29 2020-12-03 Arla Foods Amba Palatable extensively hydrolysed whey protein hydrolysates

Similar Documents

Publication Publication Date Title
WO2021201277A1 (en) Protein deamidation method
PT2117338E (en) Partially hydrolysed cereal protein
JP2011184314A (en) Muscular atrophy-preventing agent
JP2008220301A (en) Low-allergen soybean milk
CN104011199A (en) Bifidobacterium proliferation promoter
JP2017031105A (en) Agent for promoting suppression of postprandial blood sugar level increase
JP7358239B2 (en) Composition for promoting energy consumption
US11045508B2 (en) Composition for preventing or improving impaired renal function, pharmaceutical composition, food/beverage composition, and method of preventing or improving impaired renal function using the composition for preventing or improving impaired renal function
JP7062460B2 (en) Fermented milk production method
WO2023190529A1 (en) Method for producing milk protein degradation product
JP5695326B2 (en) Protein synthesis promoter
US20240158440A1 (en) Peptide and composition containing peptide as active ingredient
JP6778094B2 (en) Production method of casein enzymatic degradation product and casein enzymatic degradation product
WO2019160023A1 (en) Stroke-preventing composition
JP2021164423A (en) Composition for growth of lachnospiraceae bacteria
EP3753569A1 (en) Composition for reducing blood pressure and/or for reducing neutral fats
WO2024071404A1 (en) Novel peptide, and antioxidant composition
JP6797966B2 (en) Gastric acid protease enzyme activity inhibitor, method for producing lactoferrin composition, and lactoferrin composition
JP7369568B2 (en) Composition for promoting alcohol metabolism
JP2011084485A (en) Fat accumulation suppressor
JP6309367B2 (en) Method for producing casein hydrolyzate
WO2018051977A1 (en) Method for producing liquid soybean solution
JP2021024847A (en) Compositions for improving brain dysfunction
JP2023025199A (en) Composition for lowering blood pressure and/or reducing neutral fat
JP2022032320A (en) Production method of milk protein hydrolyzate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23780538

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2024512574

Country of ref document: JP

Kind code of ref document: A